<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:georss="http://www.georss.org/georss" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:media="http://search.yahoo.com/mrss/"
	>

<channel>
	<title>Earl&#039;s View &#187; Federal Food Drug and Cosmetic Act</title>
	<atom:link href="/tag/federal-food-drug-and-cosmetic-act/feed/" rel="self" type="application/rss+xml" />
	<link>https://earlsview.com</link>
	<description>News and Views</description>
	<lastBuildDate>Thu, 14 Nov 2013 23:54:13 +0000</lastBuildDate>
	<language>en</language>
		<sy:updatePeriod>hourly</sy:updatePeriod>
		<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.com/</generator>
<cloud domain='earlsview.com' port='80' path='/?rsscloud=notify' registerProcedure='' protocol='http-post' />
<image>
		<url>http://0.gravatar.com/blavatar/4080c5ddab1377b030361fa4f366fc3d?#038;d=http%3A%2F%2Fs2.wp.com%2Fi%2Fbuttonw-com.png</url>
		<title> &#187; Federal Food Drug and Cosmetic Act</title>
		<link>https://earlsview.com</link>
	</image>
	<atom:link rel="search" type="application/opensearchdescription+xml" href="/osd.xml" title="Earl&#039;s View" />
	<atom:link rel='hub' href='/?pushpress=hub'/>
	<item>
		<title>Where are the Transvaginal Mesh Studies Requested by the FDA? &#8211; Florida Mass Tort Attorneys, Lawyers &#124; Searcy Mass Torts</title>
		<link>https://earlsview.com/2012/09/25/where-are-the-transvaginal-mesh-studies-requested-by-the-fda-florida-mass-tort-attorneys-lawyers-searcy-mass-torts/</link>
		<comments>https://earlsview.com/2012/09/25/where-are-the-transvaginal-mesh-studies-requested-by-the-fda-florida-mass-tort-attorneys-lawyers-searcy-mass-torts/#comments</comments>
		<pubDate>Mon, 24 Sep 2012 20:41:12 +0000</pubDate>
		<dc:creator><![CDATA[earlstevens58]]></dc:creator>
				<category><![CDATA[Pelvic mesh]]></category>
		<category><![CDATA[Pelvic organ prolapse]]></category>
		<category><![CDATA[Vaginal Mesh]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Federal Food Drug and Cosmetic Act]]></category>
		<category><![CDATA[Food and Drug Administration]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Medicine]]></category>
		<category><![CDATA[Mental Health]]></category>
		<category><![CDATA[Prolapse]]></category>
		<category><![CDATA[science]]></category>
		<category><![CDATA[stress urinary incontinence]]></category>
		<category><![CDATA[SUI]]></category>
		<category><![CDATA[Switzerland]]></category>
		<category><![CDATA[Urinary incontinence]]></category>
		<category><![CDATA[US Food and Drug Administration]]></category>

		<guid isPermaLink="false">https://earlsview.com/?p=8569</guid>
		<description><![CDATA[Where are the Transvaginal Mesh Studies Requested by the FDA? &#8211; Florida Mass Tort Attorneys, Lawyers &#124; Searcy Mass Torts. &#8230;<p><a href="/2012/09/25/where-are-the-transvaginal-mesh-studies-requested-by-the-fda-florida-mass-tort-attorneys-lawyers-searcy-mass-torts/">Continue reading &#187;</a></p><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=8569&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
				<content:encoded><![CDATA[<p><a href="http://www.searcymasstort.com/blog/2012/09/24/where-are-the-transvaginal-mesh-studies-requested-by-the-fda/#.UGDExQZhLAo.wordpress">Where are the Transvaginal Mesh Studies Requested by the FDA? &#8211; Florida Mass Tort Attorneys, Lawyers | Searcy Mass Torts</a>.</p>
<h1>Where are the Transvaginal Mesh Studies Requested by the FDA?</h1>
<div class="entry-meta" style="background-color:#ffffff;border:0;margin:0;padding:0;vertical-align:baseline;color:#4e4e4e;font-family:'Myriad Pro', Helvetica, sans-serif;font-size:14px;font-style:normal;line-height:14px;"><span class="meta-prep meta-prep-author" style="background-color:transparent;border:0;margin:0;padding:0;vertical-align:baseline;background-position:initial initial;background-repeat:initial initial;">Posted on</span> <a style="background-color:transparent;border:0;margin:0;padding:0;vertical-align:baseline;color:#224a56;" title="2:45 pm" href="http://www.searcymasstort.com/blog/2012/09/24/where-are-the-transvaginal-mesh-studies-requested-by-the-fda/" rel="bookmark"><span class="entry-date" style="background-color:transparent;border:0;margin:0;padding:0;vertical-align:baseline;background-position:initial initial;background-repeat:initial initial;">September 24, 2012</span></a> <span class="meta-sep" style="background-color:transparent;border:0;margin:0;padding:0;vertical-align:baseline;background-position:initial initial;background-repeat:initial initial;">by</span> <span class="author vcard" style="background-color:transparent;border:0;margin:0;padding:0;vertical-align:baseline;background-position:initial initial;background-repeat:initial initial;"><a class="url fn n" style="background-color:transparent;border:0;margin:0;padding:0;vertical-align:baseline;color:#224a56;" title="View all posts by Brenda Fulmer" href="http://www.searcymasstort.com/blog/author/brenda-fulmer/">Brenda Fulmer</a></span></div>
<div class="entry-content" style="background-color:#ffffff;border:0;margin:0;padding:0;vertical-align:baseline;clear:none;float:right;width:525px;color:#4e4e4e;font-family:'Myriad Pro', Helvetica, sans-serif;font-size:14px;font-style:normal;line-height:14px;">
<p style="background-color:transparent;border:0;margin:15px 0;padding:0;vertical-align:baseline;line-height:1.2em;background-position:initial initial;background-repeat:initial initial;"><span style="background-color:transparent;border:0;margin:0;padding:0;vertical-align:baseline;font-size:small;background-position:initial initial;background-repeat:initial initial;">Last January 3, the <a class="zem_slink" title="Food and Drug Administration" href="http://maps.google.com/maps?ll=39.0353363,-76.9830894&amp;spn=0.01,0.01&amp;q=39.0353363,-76.9830894 (Food%20and%20Drug%20Administration)&amp;t=h" rel="geolocation" target="_blank">U.S. Food and Drug Administration (FDA)</a> <a style="background-color:transparent;border:0;margin:0;padding:0;vertical-align:baseline;color:#b53c3d;" href="http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/UroGynSurgicalMesh/default.htm" target="_blank">decided to get tough</a> on transvaginal mesh manufacturers. After noting a five-fold increase in complications among women implanted with the polypropylene mesh to treat <a class="zem_slink" title="Prolapse" href="http://en.wikipedia.org/wiki/Prolapse" rel="wikipedia" target="_blank">pelvic organ prolapse</a> (POP) and <a class="zem_slink" title="Urinary incontinence" href="http://en.wikipedia.org/wiki/Urinary_incontinence" rel="wikipedia" target="_blank">stress urinary incontinence</a> (<a class="zem_slink" title="Switzerland" href="http://maps.google.com/maps?ll=46.8333333333,8.33333333333&amp;spn=10.0,10.0&amp;q=46.8333333333,8.33333333333 (Switzerland)&amp;t=h" rel="geolocation" target="_blank">SUI</a>), the FDA asked the mesh makers to find out why.</span></p>
<p style="background-color:transparent;border:0;margin:15px 0;padding:0;vertical-align:baseline;line-height:1.2em;background-position:initial initial;background-repeat:initial initial;"><span style="background-color:transparent;border:0;margin:0;padding:0;vertical-align:baseline;font-size:small;background-position:initial initial;background-repeat:initial initial;">The FDA flexed its little-used muscle. Under Section 522 of the </span><span style="background-color:transparent;border:0;margin:0;padding:0;vertical-align:baseline;font-size:small;background-position:initial initial;background-repeat:initial initial;"><a class="zem_slink" title="Federal Food, Drug, and Cosmetic Act" href="http://en.wikipedia.org/wiki/Federal_Food%2C_Drug%2C_and_Cosmetic_Act" rel="wikipedia" target="_blank">Federal Food, Drug and Cosmetic Act</a>, </span><span style="background-color:transparent;border:0;margin:0;padding:0;vertical-align:baseline;font-size:small;background-position:initial initial;background-repeat:initial initial;">the agency can <a style="background-color:transparent;border:0;margin:0;padding:0;vertical-align:baseline;color:#b53c3d;" href="http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pss.cfm?start_search=P#P" target="_blank">request postmarket studies</a> if a device is implanted and if the complications are serious enough.</span></p>
<p style="background-color:transparent;border:0;margin:15px 0;padding:0;vertical-align:baseline;line-height:1.2em;background-position:initial initial;background-repeat:initial initial;"><span style="background-color:transparent;border:0;margin:0;padding:0;vertical-align:baseline;font-size:small;background-position:initial initial;background-repeat:initial initial;">Transvaginal mesh fit the bill and the order went out 33 manufacturers of surgical mesh for pelvic organ prolapse (POP) and seven manufacturers of single-incision mini-slings for SUI. They were to spend money and a lot of it, to come up with three years worth of monitoring to look for and report rates of mesh erosion, vaginal shortening and scarring, neuromuscular pain, revision surgeries, all of the complications that are ruining the lives of thousands of women.</span></p>
<p style="background-color:transparent;border:0;margin:15px 0;padding:0;vertical-align:baseline;line-height:1.2em;background-position:initial initial;background-repeat:initial initial;"><span style="background-color:transparent;border:0;margin:0;padding:0;vertical-align:baseline;font-size:small;background-position:initial initial;background-repeat:initial initial;">Women were to be followed for three years and adverse events reported at 6 months, 12, 18, 24 and 36.</span></p>
<p style="background-color:transparent;border:0;margin:15px 0;padding:0;vertical-align:baseline;line-height:1.2em;background-position:initial initial;background-repeat:initial initial;"><span style="background-color:transparent;border:0;margin:0;padding:0;vertical-align:baseline;font-size:small;background-position:initial initial;background-repeat:initial initial;">That was January; this is the end of September. What has happened? Absolutely nothing.<a style="background-color:transparent;border:0;margin:0;padding:0;vertical-align:baseline;color:#b53c3d;" href="http://www.searcymasstort.com/blog/wp-content/uploads/2012/04/FDA-Logo.jpg"><img class="alignright size-medium wp-image-361" style="background-color:transparent;border:none;margin:4px 0 12px 24px;padding:0;vertical-align:baseline;" title="FDA Logo" src="http://www.searcymasstort.com/blog/wp-content/uploads/2012/04/FDA-Logo-300x225.jpg" alt="" width="240" height="180" /></a></span></p>
<p style="background-color:transparent;border:0;margin:15px 0;padding:0;vertical-align:baseline;line-height:1.2em;background-position:initial initial;background-repeat:initial initial;"><span style="background-color:transparent;border:0;margin:0;padding:0;vertical-align:baseline;font-size:small;background-position:initial initial;background-repeat:initial initial;">The manufacturers were given 30 days to respond initially to the 522 orders. Nothing. Now when you look at the FDA’s own website for 522 studies you see that the plans are “pending”, or the study is pending” or “other” – in other words the follow-up that was so important to give mesh sufferers some answers just has not begun as if this were not a crisis.</span></p>
<p style="background-color:transparent;border:0;margin:15px 0;padding:0;vertical-align:baseline;line-height:1.2em;background-position:initial initial;background-repeat:initial initial;"><span style="background-color:transparent;border:0;margin:0;padding:0;vertical-align:baseline;font-size:small;background-position:initial initial;background-repeat:initial initial;">Clearly the medical device industry understands that the FDA is a lapdog watchdog agency. Has there been any action for noncompliance? Not yet. The agency has the authority to seize products off store shelves or demand a recall. Again a paper tiger.</span></p>
<p style="background-color:transparent;border:0;margin:15px 0;padding:0;vertical-align:baseline;line-height:1.2em;background-position:initial initial;background-repeat:initial initial;"><span style="background-color:transparent;border:0;margin:0;padding:0;vertical-align:baseline;font-size:small;background-position:initial initial;background-repeat:initial initial;">As if the January 3, 2012 orders for mesh studies were not enough, in May 2011, many makers of metal-on-metal (MoM) hips were required to also begin the expensive and arduous postmarketing follow-ups on people living today with metal hip implants.</span></p>
<p style="background-color:transparent;border:0;margin:15px 0;padding:0;vertical-align:baseline;line-height:1.2em;background-position:initial initial;background-repeat:initial initial;"><span style="background-color:transparent;border:0;margin:0;padding:0;vertical-align:baseline;font-size:small;background-position:initial initial;background-repeat:initial initial;">These too have <a style="background-color:transparent;border:0;margin:0;padding:0;vertical-align:baseline;color:#b53c3d;" title="Mesh Nightmare Has 1,000 Fighting Back in New Jersey" href="http://www.searcymasstort.com/blog/2012/08/30/mesh-nightmare-has-1000-fighting-back-in-new-jersey/" target="_blank">devastating life-altering injuries</a> as emerging science shows that metal debris can and does get into the blood stream of many hip implant patients, with the potential to create metallosis and necrotic tissue around the hip. The revision rate is unacceptably high, so much so that the DePuy MoM hip (Johnson &amp; Johnson) had to be pulled from the market leaving 93,000 patients wondering when their number will be up.</span></p>
<p style="background-color:transparent;border:0;margin:15px 0;padding:0;vertical-align:baseline;line-height:1.2em;background-position:initial initial;background-repeat:initial initial;"><span style="background-color:transparent;border:0;margin:0;padding:0;vertical-align:baseline;font-size:small;background-position:initial initial;background-repeat:initial initial;">Still no postmarketing plans have gotten underway. At least with metal hips, the agency’s website acknowledges the plan is “overdue”!</span></p>
<p style="background-color:transparent;border:0;margin:15px 0;padding:0;vertical-align:baseline;line-height:1.2em;background-position:initial initial;background-repeat:initial initial;"><span style="background-color:transparent;border:0;margin:0;padding:0;vertical-align:baseline;font-size:small;background-position:initial initial;background-repeat:initial initial;">They certainly are, and so is a federal agency that has some teeth.</span></p>
</div>
<h6 class="zemanta-related-title" style="font-size:1em;">Related articles</h6>
<ul class="zemanta-article-ul">
<li class="zemanta-article-ul-li"><a href="/2012/09/01/metal-on-metal-hip-trials-scheduled-for-2013-florida-mass-tort-attorneys-lawyers-searcy-mass-torts/" target="_blank">Metal-on-Metal Hip Trials Scheduled for 2013 &#8211; Florida Mass Tort Attorneys, Lawyers | Searcy Mass Torts</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/08/19/transvaginal-mesh-failure-transvaginal-mesh-litigation/" target="_blank">Transvaginal Mesh Failure | Transvaginal Mesh Litigation</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="http://clearinspiration.wordpress.com/2012/09/22/raising-awareness-pelvic-organ-prolapse-and-surgical-mesh/" target="_blank">Raising Awareness: Pelvic Organ Prolapse and Surgical Mesh</a> (clearinspiration.wordpress.com)</li>
<li class="zemanta-article-ul-li"><a href="http://www.virtual-strategy.com/2012/09/17/tennessee-woman-says-transvaginal-mesh-manufactured-cr-bard-boston-scientific-caused-inju" target="_blank">Tennessee Woman Says that Transvaginal Mesh Manufactured by C.R. Bard, Boston Scientific Caused Injuries; Lawsuit Alleges that the Pelvic Devices are Defective</a> (virtual-strategy.com)</li>
<li class="zemanta-article-ul-li"><a href="http://bradhendrickslawfirm.wordpress.com/2012/07/30/injured-by-transvaginal-meshbladder-slings-to-treat-pelvic-organ-prolapse-or-stress-urinary-incontinence/" target="_blank">Injured by Transvaginal Mesh/Bladder Slings to treat Pelvic Organ Prolapse or Stress Urinary Incontinence?</a> (bradhendrickslawfirm.wordpress.com)</li>
<li class="zemanta-article-ul-li"><a href="http://transvaginalmesh.typepad.com/blog/2012/01/fda-to-investigate-transvaginal-mesh-injuries.html" target="_blank">FDA to Investigate Transvaginal Mesh Injuries</a> (transvaginalmesh.typepad.com)</li>
<li class="zemanta-article-ul-li"><a href="http://www.prweb.com/releases/2012/8/prweb9772705.htm" target="_blank">Recent Developments in Transvaginal Mesh Could Affect Hundreds of&#8230;</a> (prweb.com)</li>
<li class="zemanta-article-ul-li"><a href="http://failsafebydesign.com/2012/07/31/guest-post-surgical-mesh-and-the-fda/" target="_blank">Guest post: Surgical Mesh and the FDA</a> (failsafebydesign.com)</li>
<li class="zemanta-article-ul-li"><a href="http://www.prweb.com/releases/2012/8/prweb9752176.htm" target="_blank">$5.5 Million Awarded to Couple in Transvaginal Mesh Lawsuit</a> (prweb.com)</li>
<li class="zemanta-article-ul-li"><a href="http://vaginalmeshcomplications.typepad.com/blog/2012/03/surgical-mesh-device-reclassified-to-be-qualified.html" target="_blank">Surgical Mesh Device Reclassified To Be Qualified</a> (vaginalmeshcomplications.typepad.com)</li>
</ul><br />Filed under: <a href='/category/pelvic-mesh/'>Pelvic mesh</a>, <a href='/category/pelvic-organ-prolapse/'>Pelvic organ prolapse</a>, <a href='/category/vaginal-mesh/'>Vaginal Mesh</a> Tagged: <a href='/tag/fda/'>FDA</a>, <a href='/tag/federal-food-drug-and-cosmetic-act/'>Federal Food Drug and Cosmetic Act</a>, <a href='/tag/food-and-drug-administration/'>Food and Drug Administration</a>, <a href='/tag/health/'>Health</a>, <a href='/tag/medicine/'>Medicine</a>, <a href='/tag/mental-health/'>Mental Health</a>, <a href='/tag/prolapse/'>Prolapse</a>, <a href='/tag/science/'>science</a>, <a href='/tag/stress-urinary-incontinence/'>stress urinary incontinence</a>, <a href='/tag/sui/'>SUI</a>, <a href='/tag/switzerland/'>Switzerland</a>, <a href='/tag/urinary-incontinence/'>Urinary incontinence</a>, <a href='/tag/us-food-and-drug-administration/'>US Food and Drug Administration</a> <a rel="nofollow" href="http://feeds.wordpress.com/1.0/gocomments/earlstevens58.wordpress.com/8569/"><img alt="" border="0" src="http://feeds.wordpress.com/1.0/comments/earlstevens58.wordpress.com/8569/" /></a> <img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=8569&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></content:encoded>
			<wfw:commentRss>https://earlsview.com/2012/09/25/where-are-the-transvaginal-mesh-studies-requested-by-the-fda-florida-mass-tort-attorneys-lawyers-searcy-mass-torts/feed/</wfw:commentRss>
		<slash:comments>4</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/6b9f08d281cf2be916ed45fc4fe2ecd7?#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">earlstevens58</media:title>
		</media:content>

		<media:content url="http://www.searcymasstort.com/blog/wp-content/uploads/2012/04/FDA-Logo-300x225.jpg" medium="image">
			<media:title type="html">FDA Logo</media:title>
		</media:content>
	</item>
		<item>
		<title>FDA Aims To Smooth Premarket Review process &#124; Bloomberg BNA</title>
		<link>https://earlsview.com/2012/08/24/fda-aims-to-smooth-premarket-review-process-bloomberg-bna/</link>
		<comments>https://earlsview.com/2012/08/24/fda-aims-to-smooth-premarket-review-process-bloomberg-bna/#comments</comments>
		<pubDate>Thu, 23 Aug 2012 20:25:05 +0000</pubDate>
		<dc:creator><![CDATA[earlstevens58]]></dc:creator>
				<category><![CDATA[510k process]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[FDA 510k process]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Center for Devices and Radiological Health]]></category>
		<category><![CDATA[draft guidances]]></category>
		<category><![CDATA[Federal Food Drug and Cosmetic Act]]></category>
		<category><![CDATA[Food & Drug Administration]]></category>
		<category><![CDATA[Medical device]]></category>
		<category><![CDATA[PMA]]></category>
		<category><![CDATA[Premarket Approval]]></category>
		<category><![CDATA[Technology]]></category>

		<guid isPermaLink="false">https://earlsview.com/?p=8170</guid>
		<description><![CDATA[FDA Aims To Smooth Premarket Review process &#124; Bloomberg BNA. Wednesday, August 22, 2012 FDA Aims To Smooth Premarket Review &#8230;<p><a href="/2012/08/24/fda-aims-to-smooth-premarket-review-process-bloomberg-bna/">Continue reading &#187;</a></p><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=8170&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
				<content:encoded><![CDATA[<p><a href="http://www.bna.com/fda-aims-smooth-b12884911320/">FDA Aims To Smooth Premarket Review process | Bloomberg BNA</a>.</p>
<p class="blogdate" style="font-weight:bold;margin:0;padding:10px 0 0;color:#666666;font-family:akzidenz-grotesk-std-bloom, Arial, sans-serif;font-style:normal;line-height:21px;background-color:#ffffff;">Wednesday, August 22, 2012</p>
<h2 class="normal" style="font-weight:normal;font-size:20px;color:#1e1e1e;padding-top:0;padding-bottom:15px;font-family:akzidenz-grotesk-std-bloom, Arial, sans-serif;font-style:normal;line-height:21px;background-color:#ffffff;">FDA Aims To Smooth Premarket Review process</h2>
<p class="byline" style="margin:-5px 0 5px;padding:0;color:#000000;font-family:akzidenz-grotesk-std-bloom, Arial, sans-serif;font-style:normal;line-height:21px;background-color:#ffffff;">by <a style="color:#0046ad;" href="http://www.bna.com/nathaniel-weixel-b12884909630/">Nathaniel Weixel</a></p>
<p>In the world of <a class="zem_slink" title="Medical device" href="http://en.wikipedia.org/wiki/Medical_device" rel="wikipedia" target="_blank">medical device</a> <a class="zem_slink" title="Review" href="http://en.wikipedia.org/wiki/Review" rel="wikipedia" target="_blank">reviews</a>, timing is everything. Device <a class="zem_slink" title="Manufacturing" href="http://www.wikinvest.com/industry/Manufacturing" rel="wikinvest" target="_blank">manufacturers</a> often claim FDA does not review their premarket <a class="zem_slink" title="Application software" href="http://en.wikipedia.org/wiki/Application_software" rel="wikipedia" target="_blank">applications</a> quickly enough. For its part, FDA has said some of the blame lies with the companies that submit applications missing key information. It&#8217;s a time consuming process to keep sending companies requests for more information. FDA officials have even said they&#8217;ve come across applications that aren&#8217;t even written in English.</p>
<p>In an effort to improve overall review times and enhance the quality of submissions, FDA in the past month has released a pair of draft guidances for industry and agency staff. The documents are pretty similar, but each covers a different type of premarket review. One addresses the idea of a &#8220;refusal to accept&#8221; policy for <a class="zem_slink" title="Federal Food, Drug, and Cosmetic Act" href="http://en.wikipedia.org/wiki/Federal_Food%2C_Drug%2C_and_Cosmetic_Act" rel="wikipedia" target="_blank">510(k)</a> applications, and the other addresses essentially the same idea for premarket approval (<a class="zem_slink" title="Premarket approval" href="http://en.wikipedia.org/wiki/Premarket_approval" rel="wikipedia" target="_blank">PMA</a>) applications. The 510(k) process is how most low and moderate-risk devices reach the market, and requires only that they be proven substantially equivalent to a device already being sold. PMAs generally require clinical trials, and are for high risk devices.</p>
<p>Both guidances outline the minimum requirements manufacturers must include in the respective premarket applications. The PMA guidance includes two checklists: acceptance criteria and filing criteria. If the manufacturer doesn&#8217;t meet the acceptance criteria, the FDA reviewer can send the application back within 15 days without having to look at any other components. The 510(k) &#8220;refusal to accept&#8221; policy is similar&#8211; if the manufacturer doesn&#8217;t meet specific criteria (outlined in a checklist), the reviewer can send it back and ask for the correct information before filing the application for a more substantial review.</p>
<p>Both guidances are still just drafts with comment periods, but FDA hopes they will lead to a much more efficient use of agency resources and a higher quality of device submissions. Comments on the 510(k) guidance are due Sept. 27, and comments on the PMA guidance are due Sept. 14.</p>
<h6 class="zemanta-related-title" style="font-size:1em;">Related articles</h6>
<ul class="zemanta-article-ul">
<li class="zemanta-article-ul-li"><a href="/2012/07/15/fda-overview-of-medical-device-regulation-information-about-mdufa-iii/" target="_blank">FDA &#8211; Overview of Medical Device Regulation &gt; Information about MDUFA III</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/14/press-announcements-fda-outlines-plans-to-provide-earlier-feedback-on-device-product-submissions/" target="_blank">Press Announcements &gt; FDA outlines plans to provide earlier feedback on device product submissions</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/07/new-fda-guidance-on-considerations-used-in-device-approval/" target="_blank">New FDA guidance on considerations used in device approval</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/08/19/dems-urge-fda-to-boost-medtech-recall-database-massdevice-com/" target="_blank">Dems urge FDA to boost medtech recall database | MassDevice.com</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/08/20/pre-market-approval-why-does-the-law-shelter-smith-nephew-others-like-them/" target="_blank">Pre Market Approval &#8211; Why does the Law shelter Smith &amp; Nephew &amp; others like them?</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/07/fda-defense-of-its-decision-to-grant-pma-to-smith-nephews-bhr/" target="_blank">FDA Defense of its Decision to Grant PMA to Smith &amp; Nephew&#8217;s BHR&#8230;</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/14/fda-to-guide-device-makers-on-marketing-application-chicagotribune-com/" target="_blank">FDA to guide device makers on marketing application &#8211; chicagotribune.com</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/08/smith-nephew-bhr-food-and-drug-administration-hhs/" target="_blank">Smith &amp; Nephew BHR &#8211; Food and Drug Administration, HHS</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/07/post-approval-studies-for-smith-nephew-bhr-not-useful/" target="_blank">Post-Approval Studies for Smith &amp; Nephew BHR &#8211; NOT USEFUL</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="http://druganddevicelaw.blogspot.com/2012/08/preemption-in-garden-state.html" target="_blank">Preemption in the Garden State</a> (druganddevicelaw.blogspot.com)</li>
</ul><br />Filed under: <a href='/category/510k-process/'>510k process</a>, <a href='/category/fda/'>FDA</a>, <a href='/category/fda-510k-process/'>FDA 510k process</a> Tagged: <a href='/tag/business/'>Business</a>, <a href='/tag/center-for-devices-and-radiological-health/'>Center for Devices and Radiological Health</a>, <a href='/tag/draft-guidances/'>draft guidances</a>, <a href='/tag/fda/'>FDA</a>, <a href='/tag/federal-food-drug-and-cosmetic-act/'>Federal Food Drug and Cosmetic Act</a>, <a href='/tag/food-drug-administration/'>Food &amp; Drug Administration</a>, <a href='/tag/medical-device/'>Medical device</a>, <a href='/tag/pma/'>PMA</a>, <a href='/tag/premarket-approval/'>Premarket Approval</a>, <a href='/tag/technology/'>Technology</a> <a rel="nofollow" href="http://feeds.wordpress.com/1.0/gocomments/earlstevens58.wordpress.com/8170/"><img alt="" border="0" src="http://feeds.wordpress.com/1.0/comments/earlstevens58.wordpress.com/8170/" /></a> <img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=8170&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></content:encoded>
			<wfw:commentRss>https://earlsview.com/2012/08/24/fda-aims-to-smooth-premarket-review-process-bloomberg-bna/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/6b9f08d281cf2be916ed45fc4fe2ecd7?#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">earlstevens58</media:title>
		</media:content>
	</item>
		<item>
		<title>Pre Market Approval &#8211; Why does the Law shelter Smith &amp; Nephew &amp; others like them?</title>
		<link>https://earlsview.com/2012/08/20/pre-market-approval-why-does-the-law-shelter-smith-nephew-others-like-them/</link>
		<comments>https://earlsview.com/2012/08/20/pre-market-approval-why-does-the-law-shelter-smith-nephew-others-like-them/#comments</comments>
		<pubDate>Sun, 19 Aug 2012 20:40:44 +0000</pubDate>
		<dc:creator><![CDATA[earlstevens58]]></dc:creator>
				<category><![CDATA[Pre market Approval]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Federal Food Drug and Cosmetic Act]]></category>
		<category><![CDATA[Food & Drug Administration]]></category>
		<category><![CDATA[Medical device]]></category>
		<category><![CDATA[Medtronic Inc. v. Lohr]]></category>
		<category><![CDATA[Premarket Approval]]></category>
		<category><![CDATA[Ralph Hall]]></category>
		<category><![CDATA[Supreme Court]]></category>

		<guid isPermaLink="false">https://earlsview.com/?p=8060</guid>
		<description><![CDATA[Premarket Approval by the FDA &#8211; why do we lose out? Reading this recent law review article by Professor Ralph Hall, &#8230;<p><a href="/2012/08/20/pre-market-approval-why-does-the-law-shelter-smith-nephew-others-like-them/">Continue reading &#187;</a></p><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=8060&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
				<content:encoded><![CDATA[<h1><a class="zem_slink" title="Premarket approval" href="http://en.wikipedia.org/wiki/Premarket_approval" rel="wikipedia" target="_blank">Premarket Approval</a> by the <a class="zem_slink" title="Food and Drug Administration" href="http://maps.google.com/maps?ll=39.0353363,-76.9830894&amp;spn=0.01,0.01&amp;q=39.0353363,-76.9830894 (Food%20and%20Drug%20Administration)&amp;t=h" rel="geolocation" target="_blank">FDA</a> &#8211; why do we lose out?</h1>
<p>Reading this <a href="http://www.reedsmith.com/files/uploads/DrugDeviceLawBlog/Hall%20Lohr%20Preemption%20Article.pdf">recent law review article</a> by Professor Ralph Hall, entitled “Rethinking Lohr: Does &#8216;SE&#8217; Mean Safe &amp; Effective, Substantially Equivalent, or Both?” 13 <a class="zem_slink" title="Minnesota" href="http://maps.google.com/maps?ll=46.0,-94.0&amp;spn=3.0,3.0&amp;q=46.0,-94.0 (Minnesota)&amp;t=h" rel="geolocation" target="_blank">Minn</a>. J. L. Sci. &amp; Tech. 737 (2012).  In brief, the article examines recent statutory and regulatory modifications to the “<a class="zem_slink" title="Federal Food, Drug, and Cosmetic Act" href="http://en.wikipedia.org/wiki/Federal_Food%2C_Drug%2C_and_Cosmetic_Act" rel="wikipedia" target="_blank">510k</a> clearance process” that have occurred since <a class="zem_slink" title="Medtronic, Inc. v. Lohr" href="http://en.wikipedia.org/wiki/Medtronic%2C_Inc._v._Lohr" rel="wikipedia" target="_blank">Medtronic, Inc. v. Lohr</a>, 518 U.S. 470 (1996), and concludes that it’s high time to re-examine Lohr’s restrictions on the use of preemption in non-PMA <a class="zem_slink" title="Medical device" href="http://en.wikipedia.org/wiki/Medical_device" rel="wikipedia" target="_blank">medical device</a> litigation:</p>
<p>This article questions whether litigants and courts have ignored major statutory and regulatory changes in the FDA’s authority over medical devices and have too simplistically followed the <a class="zem_slink" title="The Supreme Court of the United States" href="http://www.history.com/topics/supreme-court" rel="historycom" target="_blank">Supreme Court</a>’s decision in Medtronic, Inc. v. Lohr.  We believe that this is exactly the situation and that the precedential value of Lohr is highly questionable.</p>
<p><a href="http://www.reedsmith.com/files/uploads/DrugDeviceLawBlog/Hall%20Lohr%20Preemption%20Article.pdf">13 Minn. J. L. Sci. &amp; Tech.</a> at 739 (footnote omitted).  Professor Hall concludes, after reviewing the evolution of the 510k system in detail, that unlike the 1982 device clearance in Lohr, the FDA now (and has for some time) predicates device clearances on “safety and effectiveness” criteria:</p>
<p>Today, the FDA makes safety and effectiveness determinations for 510(k) medical devices in determining the classification of the new device, compared to the predicate device, and whether the new device is substantially equivalent or not substantially equivalent.</p>
<p><a href="http://www.reedsmith.com/files/uploads/DrugDeviceLawBlog/Hall%20Lohr%20Preemption%20Article.pdf">13 Minn. J. L. Sci. &amp; Tech.</a> at 789.</p>
<p>While much of Professor Hall’s article explores express preemption, we were gratified to see a discussion of the Mensing “impossibility” approach to implied preemption as applied to medical devices under the FDA’s regulations governing medical device alterations. <a href="http://www.reedsmith.com/files/uploads/DrugDeviceLawBlog/Hall%20Lohr%20Preemption%20Article.pdf">13 Minn. J. L. Sci. &amp; Tech.</a> at 768-769.  We’ve had exactly the <a href="http://druganddevicelaw.blogspot.com/2011/07/implied-preemption-and-medical-devices.html">same thoughts</a> ourselves.</p>
<p>Since most medical devices are not PMA approved, and preemption is the strongest legal defense there is, if you defend these sorts of products, we think you’ll find Professor Hall’s article most illuminating.</p>
<p>That’s the long one.  Our other recommendation requires a lot less reading and (perhaps) more thinking.  The other day, four life sciences industry groups sent a <a href="http://www.fulbright.com/e_templates/Data/Alerts/TradeAssociationSunshineLettertoCMSAug142012FINAL.pdf">public letter</a> (thanks to <a href="http://www.fulbright.com/">Fulbright and Jaworski</a> for the link) to the <a class="zem_slink" title="Centers for Medicare and Medicaid Services" href="http://www.cms.gov" rel="homepage" target="_blank">Centers for Medicare and Medicaid Services</a> asking that CMS hurry up and finalize its reporting regulations for the <a href="http://thomas.loc.gov/cgi-bin/query/z?c111:S.301">Physician Payments Sunshine Act</a>.</p>
<p>Huh?  Do you even know what that is?</p>
<p>You should, because it will affect your clients, and might well affect how you prepare and try your cases.</p>
<p>As the recent letter explains, as part of the Affordable Healthcare Act − which the Supreme Court recently upheld in large part − the health care industry is now required to report “payments to teaching hospitals, physicians, and physician ownership and investment interests.”  Exactly what should be reported and how is now being sorted out.  Read the letter for details.</p>
<p>Then think a bit.</p>
<p>These reports of “payments” will be public.  Various financial ties between physicians − the plaintiffs’ prescribers/treaters, and both sides’ (but mostly our) experts − will soon be “transparent,” that is, generally available.  Expect more <a class="zem_slink" title="Learned intermediary" href="http://en.wikipedia.org/wiki/Learned_intermediary" rel="wikipedia" target="_blank">learned intermediary rule</a> challenges to physician “independence” due to financial ties − something we’ve discussed <a href="http://druganddevicelaw.blogspot.com/2011/11/ugly-texas-decision-ignores-erie.html">here</a>.</p>
<p>Think about how this new statute is going to impact your cases; what juries will think about this type of information.  There’s nothing in the legislation addressing (that is to say, precluding) admissibility of reported data in civil litigation.</p>
<p>Then also think about how to level the playing field.</p>
<p>There’s no reason not to seek discovery from plaintiffs’ experts to determine if they’ve received similar emoluments from plaintiff-side groups.  It gets back to the level playing field we’ve argued for, particularly in the context if informal physician interviews.  If this kind of information is discoverable/admissible as to our side, it should be equally discoverable/admissible as to entities on the other side of the “v.”</p>
<p>Source: Bexis to <a href="http://druganddevicelaw.blogspot.com/2012/08/summer-reading_16.html">Drug and Device Law</a> at 8/16/2012 03:55:00 PM</p>
<h6 class="zemanta-related-title" style="font-size:1em;">Related articles</h6>
<ul class="zemanta-article-ul">
<li class="zemanta-article-ul-li"><a href="http://druganddevicelaw.blogspot.com/2012/08/summer-reading_16.html" target="_blank">Summer Reading</a> (druganddevicelaw.blogspot.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/08/18/loophole-in-fdas-approval-process-for-medical-devices-prompts-letter-from-congress-forbes/" target="_blank">Loophole in FDA&#8217;s Approval Process for Medical Devices Prompts Letter from Congress &#8211; Forbes</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/08/19/dems-urge-fda-to-boost-medtech-recall-database-massdevice-com/" target="_blank">Dems urge FDA to boost medtech recall database | MassDevice.com</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/06/17/fda-pma-how-this-hides-the-guilty-and-stops-the-damaged-and-suffering-from-getting-justice-smith-nephew/" target="_blank">FDA PMA &#8211; how this hides the guilty and stops The Damaged and Suffering from getting Justice &#8211; Smith &amp; Nephew</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/26/lets-keep-the-heat-up-on-smith-and-nephew-our-numbers-vs-their-tactical-legal-maneuvering/" target="_blank">Let&#8217;s Keep the Heat up on Smith and Nephew &#8211; Our Numbers vs. their Tactical Legal Maneuvering</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/08/19/smith-nephew-r3-hip-liner-recall-lawyer-hip-implant-lawsuit-attorney/" target="_blank">Smith &amp; Nephew R3 Hip Liner Recall Lawyer &#8211; Hip Implant Lawsuit Attorney</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/06/30/medical-device-the-senate-passes-unparalleled-medical-device-user-fee-act/" target="_blank">Medical Device &#8221; The Senate Passes Unparalleled Medical Device User Fee Act</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/07/fda-defense-of-its-decision-to-grant-pma-to-smith-nephews-bhr/" target="_blank">FDA Defense of its Decision to Grant PMA to Smith &amp; Nephew&#8217;s BHR&#8230;</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/15/fda-overview-of-medical-device-regulation-information-about-mdufa-iii/" target="_blank">FDA &#8211; Overview of Medical Device Regulation &gt; Information about MDUFA III</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/08/18/rottenstein-law-group-reports-on-research-paper-concluding-fdas-medical-device-approval-process-needs-reform/" target="_blank">Rottenstein Law Group Reports on Research Paper Concluding FDA&#8217;s Medical Device Approval Process Needs Reform</a> (earlsview.com)</li>
</ul><br />Filed under: <a href='/category/pre-market-approval-2/'>Pre market Approval</a> Tagged: <a href='/tag/fda/'>FDA</a>, <a href='/tag/federal-food-drug-and-cosmetic-act/'>Federal Food Drug and Cosmetic Act</a>, <a href='/tag/food-drug-administration/'>Food &amp; Drug Administration</a>, <a href='/tag/medical-device/'>Medical device</a>, <a href='/tag/medtronic-inc-v-lohr/'>Medtronic Inc. v. Lohr</a>, <a href='/tag/premarket-approval/'>Premarket Approval</a>, <a href='/tag/ralph-hall/'>Ralph Hall</a>, <a href='/tag/supreme-court/'>Supreme Court</a> <a rel="nofollow" href="http://feeds.wordpress.com/1.0/gocomments/earlstevens58.wordpress.com/8060/"><img alt="" border="0" src="http://feeds.wordpress.com/1.0/comments/earlstevens58.wordpress.com/8060/" /></a> <img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=8060&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></content:encoded>
			<wfw:commentRss>https://earlsview.com/2012/08/20/pre-market-approval-why-does-the-law-shelter-smith-nephew-others-like-them/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/6b9f08d281cf2be916ed45fc4fe2ecd7?#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">earlstevens58</media:title>
		</media:content>
	</item>
		<item>
		<title>Dems urge FDA to boost medtech recall database &#124; MassDevice.com</title>
		<link>https://earlsview.com/2012/08/19/dems-urge-fda-to-boost-medtech-recall-database-massdevice-com/</link>
		<comments>https://earlsview.com/2012/08/19/dems-urge-fda-to-boost-medtech-recall-database-massdevice-com/#comments</comments>
		<pubDate>Sat, 18 Aug 2012 14:19:34 +0000</pubDate>
		<dc:creator><![CDATA[earlstevens58]]></dc:creator>
				<category><![CDATA[510k process]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[FDA 510k process]]></category>
		<category><![CDATA[dangerous loophole]]></category>
		<category><![CDATA[Database]]></category>
		<category><![CDATA[Ed Markey]]></category>
		<category><![CDATA[Federal Food Drug and Cosmetic Act]]></category>
		<category><![CDATA[Food & Drug Administration]]></category>
		<category><![CDATA[Jeffrey Shuren]]></category>
		<category><![CDATA[Massachusetts]]></category>
		<category><![CDATA[Medical device]]></category>
		<category><![CDATA[premarket notification]]></category>
		<category><![CDATA[science]]></category>
		<category><![CDATA[Technology]]></category>

		<guid isPermaLink="false">https://earlsview.com/?p=8017</guid>
		<description><![CDATA[Dems urge FDA to boost medtech recall database &#124; MassDevice.com On Call &#124; MassDevice &#8211; Medical Device Industry News. Dems &#8230;<p><a href="/2012/08/19/dems-urge-fda-to-boost-medtech-recall-database-massdevice-com/">Continue reading &#187;</a></p><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=8017&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
				<content:encoded><![CDATA[<p><a href="http://www.massdevice.com/news/dems-urge-fda-boost-medtech-recall-database-massdevicecom-call">Dems urge FDA to boost medtech recall database | MassDevice.com On Call | MassDevice &#8211; Medical Device Industry News</a>.</p>
<h1>Dems urge FDA to boost medtech recall database | MassDevice.com On Call</h1>
<p>August 17, 2012 by MassDevice staff</p>
<p>A duo of <a class="zem_slink" title="Democratic Party (United States)" href="http://www.democrats.org/" rel="homepage" target="_blank">Democrats</a> urge the FDA to &#8220;overhaul and streamline&#8221; recall and <a class="zem_slink" title="Federal Food, Drug, and Cosmetic Act" href="http://en.wikipedia.org/wiki/Federal_Food%2C_Drug%2C_and_Cosmetic_Act" rel="wikipedia" target="_blank">510(k)</a> databases to ensure new products aren&#8217;t winning clearance on flawed designs.</p>
<p>MASSDEVICE ON CALL — <a class="zem_slink" title="Member of Congress" href="http://en.wikipedia.org/wiki/Member_of_Congress" rel="wikipedia" target="_blank">Congressmen</a> Rep. <a class="zem_slink" title="Ed Markey" href="http://en.wikipedia.org/wiki/Ed_Markey" rel="wikipedia" target="_blank">Edward Markey</a> (D-<a class="zem_slink" title="Massachusetts" href="http://maps.google.com/maps?ll=42.3,-71.8&amp;spn=3.0,3.0&amp;q=42.3,-71.8 (Massachusetts)&amp;t=h" rel="geolocation" target="_blank">Mass.</a>) and Sen. Jeff Merkely (D-Ore.) called on the FDA to &#8220;overhaul and streamline&#8221; its recalls and 510(k) premarket notification database.</p>
<p>The legislators want the FDA to ensure that the data is &#8220;publicly available and easily searchable&#8221; so that it better serves the needs of medical device reviewers, manufacturers and patients, according to a letter they jointly issued to FDA medical devices director Dr. <a class="zem_slink" title="Jeffrey Shuren" href="http://en.wikipedia.org/wiki/Jeffrey_Shuren" rel="wikipedia" target="_blank">Jeffrey Shuren</a>.</p>
<p>&#8220;Current law requires FDA to clear a device shown to be substantially equivalent to a predicate, even in cases where the new product contains the same flaws as an earlier model,&#8221; the pair wrote. &#8220;Database improvements would enhance the transparency of the 510(k) process and help manufacturers avoid using recalled devices as predicates that may put their own devices at risk for future enforcement action.&#8221;</p>
<p>Ultimately the lawmakers hope to see the FDA gain the authority to reject medical devices which rely on recalled devices as predicates, but in the meantime hope that making recall data more accessible and transparent will &#8220;enhance awareness among the public and medical professionals of the potential dangers of medical devices that are based on flawed predicates,&#8221; according to the letter.</p>
<h6 class="zemanta-related-title" style="font-size:1em;">Related articles</h6>
<ul class="zemanta-article-ul">
<li class="zemanta-article-ul-li"><a href="/2012/06/30/medical-device-the-senate-passes-unparalleled-medical-device-user-fee-act/" target="_blank">Medical Device &#8221; The Senate Passes Unparalleled Medical Device User Fee Act</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="http://leftistmoderatespeak.com/2012/08/17/forget-asking-for-a-link-exchange%c2%85/" target="_blank">Forget Asking For A Link Exchange</a> (leftistmoderatespeak.com)</li>
<li class="zemanta-article-ul-li"><a href="http://www.prweb.com/releases/prweb2012/3/prweb9255200.htm" target="_blank">Rottenstein Law Group Applauds FDA Device Chief&#8217;s Recommendation To Close Dangerous Loophole In Agency&#8217;s Medical-Device Approval Process</a> (prweb.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/08/fda-proposes-new-rule-that-would-require-medical-devices-such-as-surgical-mesh-to-carry-unique-device-identifier/" target="_blank">FDA Proposes New Rule That Would Require Medical Devices Such as Surgical Mesh to Carry Unique Device Identifier</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/08/fda-releases-proposed-udi-rule-reaction-generally-positive/" target="_blank">FDA releases proposed UDI rule; reaction generally positive</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="http://leftistmoderatespeak.com/2012/08/16/shifting-income-sources-of-the-aged-2/" target="_blank">Shifting Income Sources of the Aged</a> (leftistmoderatespeak.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/15/fda-overview-of-medical-device-regulation-information-about-mdufa-iii/" target="_blank">FDA &#8211; Overview of Medical Device Regulation &gt; Information about MDUFA III</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/15/medical-device-id-proposal-unveiled-govinfosecurity/" target="_blank">Medical Device ID Proposal Unveiled &#8211; GovInfoSecurity</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/15/fda-to-help-medical-device-sales-with-expanded-pre-market-feedback-program/" target="_blank">FDA to help medical device sales with expanded pre-market feedback program</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="http://leftistmoderatespeak.com/2012/08/17/the-ediscovery-paradigm-shift-the-legal-profession-found-the-twenty-first-century-ignorance-is-bliss-no-longer/" target="_blank">The eDiscovery Paradigm Shift: The Legal Profession Found the Twenty-First Century: Ignorance is bliss no longer</a> (leftistmoderatespeak.com)</li>
</ul><br />Filed under: <a href='/category/510k-process/'>510k process</a>, <a href='/category/fda/'>FDA</a>, <a href='/category/fda-510k-process/'>FDA 510k process</a> Tagged: <a href='/tag/dangerous-loophole/'>dangerous loophole</a>, <a href='/tag/database/'>Database</a>, <a href='/tag/ed-markey/'>Ed Markey</a>, <a href='/tag/fda/'>FDA</a>, <a href='/tag/federal-food-drug-and-cosmetic-act/'>Federal Food Drug and Cosmetic Act</a>, <a href='/tag/food-drug-administration/'>Food &amp; Drug Administration</a>, <a href='/tag/jeffrey-shuren/'>Jeffrey Shuren</a>, <a href='/tag/massachusetts/'>Massachusetts</a>, <a href='/tag/medical-device/'>Medical device</a>, <a href='/tag/premarket-notification/'>premarket notification</a>, <a href='/tag/science/'>science</a>, <a href='/tag/technology/'>Technology</a> <a rel="nofollow" href="http://feeds.wordpress.com/1.0/gocomments/earlstevens58.wordpress.com/8017/"><img alt="" border="0" src="http://feeds.wordpress.com/1.0/comments/earlstevens58.wordpress.com/8017/" /></a> <img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=8017&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></content:encoded>
			<wfw:commentRss>https://earlsview.com/2012/08/19/dems-urge-fda-to-boost-medtech-recall-database-massdevice-com/feed/</wfw:commentRss>
		<slash:comments>4</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/6b9f08d281cf2be916ed45fc4fe2ecd7?#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">earlstevens58</media:title>
		</media:content>
	</item>
		<item>
		<title>Loophole in FDA&#8217;s Approval Process for Medical Devices Prompts Letter from Congress &#8211; Forbes</title>
		<link>https://earlsview.com/2012/08/18/loophole-in-fdas-approval-process-for-medical-devices-prompts-letter-from-congress-forbes/</link>
		<comments>https://earlsview.com/2012/08/18/loophole-in-fdas-approval-process-for-medical-devices-prompts-letter-from-congress-forbes/#comments</comments>
		<pubDate>Sat, 18 Aug 2012 13:54:12 +0000</pubDate>
		<dc:creator><![CDATA[earlstevens58]]></dc:creator>
				<category><![CDATA[510k process]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[FDA 510k process]]></category>
		<category><![CDATA[Center for Devices and Radiological Health]]></category>
		<category><![CDATA[Congress]]></category>
		<category><![CDATA[Ed Markey]]></category>
		<category><![CDATA[edward markey]]></category>
		<category><![CDATA[Federal Food Drug and Cosmetic Act]]></category>
		<category><![CDATA[Food & Drug Administration]]></category>
		<category><![CDATA[internet]]></category>
		<category><![CDATA[Jeff Merkley]]></category>
		<category><![CDATA[Medical device]]></category>
		<category><![CDATA[science]]></category>
		<category><![CDATA[Technology]]></category>

		<guid isPermaLink="false">https://earlsview.com/?p=8009</guid>
		<description><![CDATA[Loophole in FDA&#8217;s Approval Process for Medical Devices Prompts Letter from Congress &#8211; Forbes. Loophole in FDA&#8217;s Approval Process for &#8230;<p><a href="/2012/08/18/loophole-in-fdas-approval-process-for-medical-devices-prompts-letter-from-congress-forbes/">Continue reading &#187;</a></p><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=8009&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
				<content:encoded><![CDATA[<p><a href="http://www.forbes.com/sites/gerganakoleva/2012/08/17/loophole-in-fdas-approval-process-for-medical-devices-prompts-letter-from-congress/">Loophole in FDA&#8217;s Approval Process for Medical Devices Prompts Letter from Congress &#8211; Forbes</a>.</p>
<h1>Loophole in FDA&#8217;s Approval Process for Medical Devices Prompts Letter from Congress</h1>
<p>A proposal to keep potentially flawed medical devices from entering the market made its way to the <a class="zem_slink" title="Food and Drug Administration" href="http://maps.google.com/maps?ll=39.0353363,-76.9830894&amp;spn=0.01,0.01&amp;q=39.0353363,-76.9830894 (Food%20and%20Drug%20Administration)&amp;t=h" rel="geolocation" target="_blank">Food and Drug Administration</a> this week, with two congressmen asking the agency to reform its approval process for new devices that are modeled after existing, but later recalled, products.</p>
<p>In a letter addressed to the head of the FDA’s <a class="zem_slink" title="Center for Devices and Radiological Health" href="http://en.wikipedia.org/wiki/Center_for_Devices_and_Radiological_Health" rel="wikipedia" target="_blank">Center for Devices and Radiological Health</a>, Rep. <a class="zem_slink" title="Ed Markey" href="http://en.wikipedia.org/wiki/Ed_Markey" rel="wikipedia" target="_blank">Edward Markey</a> (D-<a class="zem_slink" title="Master of Arts (postgraduate)" href="http://en.wikipedia.org/wiki/Master_of_Arts_%28postgraduate%29" rel="wikipedia" target="_blank">MA</a>) and Sen. <a class="zem_slink" title="Jeff Merkley" href="http://merkley.senate.gov" rel="homepage" target="_blank">Jeff Merkley</a> (D-OR) say the current process used to fast-track such devices, known as <a class="zem_slink" title="Federal Food, Drug, and Cosmetic Act" href="http://en.wikipedia.org/wiki/Federal_Food%2C_Drug%2C_and_Cosmetic_Act" rel="wikipedia" target="_blank">510(k)</a>, “opens the door for defective devices to make their way onto the market and jeopardize <a class="zem_slink" title="Patient safety" href="http://en.wikipedia.org/wiki/Patient_safety" rel="wikipedia" target="_blank">patient safety</a>.”</p>
<p>The lawmakers suggest the process itself is flawed because it essentially requires regulators to approve a new product without <a class="zem_slink" title="Clinical trials" href="http://www.wikinvest.com/concept/Clinical_trials" rel="wikinvest" target="_blank">clinical trial</a> data if its manufacturer can show it is similar to an already legally marketed device – a “predicate” – but says nothing of how the agency should act when the predicate has been found to be defective.</p>
<p><strong>“Already, thousands of patients have been harmed — in some cases grievously and irrevocably — by medical devices that were modeled after recalled devices,” the letter states.</strong></p>
<p>The current law, displaying a peculiar lack of hindsight, virtually guarantees that the FDA will clear new products proven to be sufficiently similar to ones already approved, even in cases when they contain the same design flaws that have prompted recalls of the latter.</p>
<p>The danger in approving medical devices through the expedited process is due not only to the fact that the evaluations don’t factor in safety concerns matched to the original product, but also because they don’t require clinical testing in humans, thus doubling the potential risk of failure.</p>
<p>The congressmen say the FDA’s authority should be expanded to allow it to reject a device if its blueprint contains the same likelihood for malfunction that led to the recall of an earlier product. In the meantime, they are asking the agency to update its 510(k) database to reflect which new devices have been cleared despite being based on a model that was later found to be defective.</p>
<h6 class="zemanta-related-title" style="font-size:1em;">Related articles</h6>
<ul class="zemanta-article-ul">
<li class="zemanta-article-ul-li"><a href="/2012/06/30/medical-device-the-senate-passes-unparalleled-medical-device-user-fee-act/" target="_blank">Medical Device &#8221; The Senate Passes Unparalleled Medical Device User Fee Act</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="http://www.prweb.com/releases/prweb2012/3/prweb9255200.htm" target="_blank">Rottenstein Law Group Applauds FDA Device Chief&#8217;s Recommendation To Close Dangerous Loophole In Agency&#8217;s Medical-Device Approval Process</a> (prweb.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/15/fda-overview-of-medical-device-regulation-information-about-mdufa-iii/" target="_blank">FDA &#8211; Overview of Medical Device Regulation &gt; Information about MDUFA III</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/28/protection-to-paranoia-for-fdas-surveillance-program-editorials-tri-cityherald-com/" target="_blank">Protection to paranoia for FDA&#8217;s surveillance program | Editorials | Tri-CityHerald.com</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/08/governmental-oversight-of-potentially-dangerous-medical-devices-us-politics-today/" target="_blank">Governmental Oversight of Potentially Dangerous Medical Devices &#8211; US Politics Today</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/15/fda-to-help-medical-device-sales-with-expanded-pre-market-feedback-program/" target="_blank">FDA to help medical device sales with expanded pre-market feedback program</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/08/14/the-us-medical-device-market-is-a-dinosaur-mike-comments/" target="_blank">The US Medical Device Market is a Dinosaur &#8211; Mike comments</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/14/press-announcements-fda-outlines-plans-to-provide-earlier-feedback-on-device-product-submissions/" target="_blank">Press Announcements &gt; FDA outlines plans to provide earlier feedback on device product submissions</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/08/fda-releases-proposed-udi-rule-reaction-generally-positive/" target="_blank">FDA releases proposed UDI rule; reaction generally positive</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/14/fda-to-guide-device-makers-on-marketing-application-chicagotribune-com/" target="_blank">FDA to guide device makers on marketing application &#8211; chicagotribune.com</a> (earlsview.com)</li>
</ul><br />Filed under: <a href='/category/510k-process/'>510k process</a>, <a href='/category/fda/'>FDA</a>, <a href='/category/fda-510k-process/'>FDA 510k process</a> Tagged: <a href='/tag/center-for-devices-and-radiological-health/'>Center for Devices and Radiological Health</a>, <a href='/tag/congress/'>Congress</a>, <a href='/tag/ed-markey/'>Ed Markey</a>, <a href='/tag/edward-markey/'>edward markey</a>, <a href='/tag/fda/'>FDA</a>, <a href='/tag/federal-food-drug-and-cosmetic-act/'>Federal Food Drug and Cosmetic Act</a>, <a href='/tag/food-drug-administration/'>Food &amp; Drug Administration</a>, <a href='/tag/internet/'>internet</a>, <a href='/tag/jeff-merkley/'>Jeff Merkley</a>, <a href='/tag/medical-device/'>Medical device</a>, <a href='/tag/science/'>science</a>, <a href='/tag/technology/'>Technology</a> <a rel="nofollow" href="http://feeds.wordpress.com/1.0/gocomments/earlstevens58.wordpress.com/8009/"><img alt="" border="0" src="http://feeds.wordpress.com/1.0/comments/earlstevens58.wordpress.com/8009/" /></a> <img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=8009&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></content:encoded>
			<wfw:commentRss>https://earlsview.com/2012/08/18/loophole-in-fdas-approval-process-for-medical-devices-prompts-letter-from-congress-forbes/feed/</wfw:commentRss>
		<slash:comments>8</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/6b9f08d281cf2be916ed45fc4fe2ecd7?#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">earlstevens58</media:title>
		</media:content>
	</item>
		<item>
		<title>Smith &amp; Nephew BHR &#8211; Food and Drug Administration, HHS</title>
		<link>https://earlsview.com/2012/07/08/smith-nephew-bhr-food-and-drug-administration-hhs/</link>
		<comments>https://earlsview.com/2012/07/08/smith-nephew-bhr-food-and-drug-administration-hhs/#comments</comments>
		<pubDate>Sun, 08 Jul 2012 02:19:33 +0000</pubDate>
		<dc:creator><![CDATA[earlstevens58]]></dc:creator>
				<category><![CDATA[510k process]]></category>
		<category><![CDATA[Birmingham Hip Resurfacing]]></category>
		<category><![CDATA[Smith & Nephew]]></category>
		<category><![CDATA[Smith & Nephew BHR Problems]]></category>
		<category><![CDATA[Constraint]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Federal Food Drug and Cosmetic Act]]></category>
		<category><![CDATA[Food & Drug Administration]]></category>
		<category><![CDATA[hip resurfacing]]></category>
		<category><![CDATA[Medical device]]></category>
		<category><![CDATA[NephewSmith]]></category>
		<category><![CDATA[Premarket Approval]]></category>
		<category><![CDATA[UNited States]]></category>

		<guid isPermaLink="false">https://earlsview.com/?p=7521</guid>
		<description><![CDATA[www.gpo.gov/fdsys/pkg/CFR-2011-title21-vol8/pdf/CFR-2011-title21-vol8-sec888-5.pdf. PDF File: Food and Drug Administration, HHS CFR-2011-title21-vol8-sec888-5 Food and Drug Administration, HHS 513(f) of the act) into class III &#8230;<p><a href="/2012/07/08/smith-nephew-bhr-food-and-drug-administration-hhs/">Continue reading &#187;</a></p><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=7521&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
				<content:encoded><![CDATA[<p><a href="http://www.gpo.gov/fdsys/pkg/CFR-2011-title21-vol8/pdf/CFR-2011-title21-vol8-sec888-5.pdf">www.gpo.gov/fdsys/pkg/CFR-2011-title21-vol8/pdf/CFR-2011-title21-vol8-sec888-5.pdf</a>.</p>
<p><a class="zem_slink" title="Portable Document Format" href="http://www.adobe.com/devnet/pdf/pdf_reference_archive.html" rel="homepage" target="_blank">PDF File</a>: <a href="http://earlstevens58.files.wordpress.com/2012/07/food-and-drug-administration-hhs-cfr-2011-title21-vol8-sec888-5.pdf">Food and Drug Administration, HHS CFR-2011-title21-vol8-sec888-5</a></p>
<h2 class="Heading10" style="margin:0 0 5.65pt 1pt;text-align:justify;line-height:10pt;page-break-after:avoid;background-position:initial initial;background-repeat:initial initial;"><a name="bookmark0"></a><span class="Barcode"><a class="zem_slink" title="Food and Drug Administration" href="http://maps.google.com/maps?ll=39.0353363,-76.9830894&amp;spn=0.01,0.01&amp;q=39.0353363,-76.9830894 (Food%20and%20Drug%20Administration)&amp;t=h" rel="geolocation" target="_blank">Food and Drug Administration</a>, HHS</span></h2>
<p>513(f) of the act) into class III without any <a title="Grace period" href="http://en.wikipedia.org/wiki/Grace_period" rel="wikipedia" target="_blank">grace period</a> and FDA must have issued an order approving a <a title="Premarket approval" href="http://en.wikipedia.org/wiki/Premarket_approval" rel="wikipedia" target="_blank">PMA</a> or de­claring completed a <a title="Peruvian Democratic Party" href="http://en.wikipedia.org/wiki/Peruvian_Democratic_Party" rel="wikipedia" target="_blank">PDP</a> for the device before the device is commercially dis­tributed unless it is reclassified. If FDA knows that a device being com­mercially <a class="zem_slink" title="Distributed computing" href="http://en.wikipedia.org/wiki/Distributed_computing" rel="wikipedia" target="_blank">distributed</a> may be a ‘‘new’’ device as defined in this section be­cause of any new intended use or other reasons, FDA may codify the statutory classification of the device into class III for such new use. Accordingly, the <a title="Regulation" href="http://en.wikipedia.org/wiki/Regulation" rel="wikipedia" target="_blank">regulation</a> for such a class III device states that as of the enactment date of the amendments, May 28, 1976, the de­vice must have an approval under sec­tion 515 of the act before commercial distribution.</p>
<p>(c) A device identified in a regulation in this part that is classified into class III and that is subject to the transi­tional provisions of section 520(1) of the act is automatically classified by stat­ute into class III and must have an ap­proval under section 515 of the act be­fore being commercially distributed. Accordingly, the regulation for such a class III transitional device states that as of the enactment date of the amend­ments, May 28, 1976, the device must have an approval under section 515 of the act before commercial distribution.</p>
<p class="Barcode0" style="margin-left:1pt;text-align:justify;line-height:10pt;background-position:initial initial;background-repeat:initial initial;"><strong><span style="color:black;" lang="EN-US">§ 888.5 <a class="zem_slink" title="Road surface" href="http://en.wikipedia.org/wiki/Road_surface" rel="wikipedia" target="_blank">Resurfacing</a> technique.</span></strong></p>
<p>Because of resurfacing techniques, certain joint <a title="Prosthesis" href="http://en.wikipedia.org/wiki/Prosthesis" rel="wikipedia" target="_blank">prostheses</a> require far less bone resection than other devices in­tended to repair or replace the same joint. The amount of bone resection may or may not affect the safety and effectiveness of the implantation of the prosthesis. When a resurfacing tech­nique is used, the name of the pros­thesis includes this information.</p>
<p class="Barcode0" style="margin-left:1pt;text-align:justify;line-height:10pt;background-position:initial initial;background-repeat:initial initial;"><strong><span style="color:black;" lang="EN-US">§ 888.6 Degree of <a class="zem_slink" title="Constraint (mathematics)" href="http://en.wikipedia.org/wiki/Constraint_%28mathematics%29" rel="wikipedia" target="_blank">constraint</a>.</span></strong></p>
<p>Certain joint prostheses provide more constraint of joint movement than oth­ers. FDA believes that the degree of constraint is an important factor af­fecting the safety and effectiveness of orthopedic prostheses. FDA is defining the following standard terms for cat­egorizing the degree of constraint.</p>
<p><!--[if !supportLists]-->(a)   <!--[endif]-->A “constrained” joint prosthesis is used for joint replacement and pre­vents dislocation of the prosthesis in more than one anatomic plane and con-sists of either a single, flexible, across- the-joint component or more than one componentlinked together or affined.</p>
<p><!--[if !supportLists]--><span style="color:black;" lang="EN-US">(b)<span style="font-family:'Times New Roman';font-size:7pt;font-style:normal;line-height:normal;">    </span></span><!--[endif]--><span style="color:black;" lang="EN-US">A ‘‘semi-constrained’’ joint pros­thesis is used for partial or <a class="zem_slink" title="Joint replacement" href="http://en.wikipedia.org/wiki/Joint_replacement" rel="wikipedia" target="_blank">total joint replacement</a> and limits translation and rotation of the prosthesis in one or more planes via the geometry of its ar­ticulating surfaces. It has no across- the-joint linkage.</span></p>
<p><!--[if !supportLists]--><span style="color:black;" lang="EN-US">(c)<span style="font-family:'Times New Roman';font-size:7pt;font-style:normal;line-height:normal;">    </span></span><!--[endif]--><span style="color:black;" lang="EN-US">A ‘‘non-constrained’’ joint pros­thesis is used for partial or total joint replacement and restricts minimally prosthesis movement in one or more planes. Its components have no across- the-joint linkage.</span></p>
<p><strong>§ 888.9 Limitations of exemptions from section 510(k) of the <a title="Federal Food, Drug, and Cosmetic Act" href="http://en.wikipedia.org/wiki/Federal_Food%2C_Drug%2C_and_Cosmetic_Act" rel="wikipedia" target="_blank">Federal Food, Drug, and Cosmetic Act</a> (the act).</strong></p>
<p>The exemption from the requirement of <a class="zem_slink" title="Medical device" href="http://en.wikipedia.org/wiki/Medical_device" rel="wikipedia" target="_blank">premarket notification</a> (section 510(k) of the act) for a generic type of class I or II device is only to the extent that the device has existing or reason­ably foreseeable characteristics of commercially distributed devices with­in that generic type or, in the case of in vitro diagnostic devices, only to the extent that misdiagnosis as a result of using the device would not be associ­ated with high morbidity or mortality. Accordingly, manufacturers of any commercially distributed class I or II device for which FDA has granted an exemption from the requirement of premarket notification must still sub­mit a premarket notification to FDA before introducing or delivering for in­troduction into interstate commerce for commercial distribution the device when:</p>
<p><!--[if !supportLists]-->(a)    <!--[endif]-->The device is intended for a use different from the intended use of a le­gally marketed device in that generic type of device; e.g., the device is in­tended for a different medical purpose, or the device is intended for lay use where the former intended use was by health care professionals only;</p>
<p><!--[if !supportLists]-->(b)    <!--[endif]-->The modified device operates using a different fundamental sci­entific technology than a legally mar­keted device in that generic type of de­vice; e.g., a surgical instrument cuts tissue with a laser beam rather than with a sharpened metal blade, or an in vitro diagnostic device detects or iden­tifies infectious agents by using</p>
<h6 class="zemanta-related-title" style="font-size:1em;">Related articles</h6>
<ul class="zemanta-article-ul">
<li class="zemanta-article-ul-li"><a href="/2012/07/07/fda-defense-of-its-decision-to-grant-pma-to-smith-nephews-bhr/" target="_blank">FDA Defense of its Decision to Grant PMA to Smith &amp; Nephew&#8217;s BHR&#8230;</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/07/fda-pre-market-approval-pma-of-birmingham-hip-resurfacing-bhr-system-p040033/" target="_blank">FDA Pre Market Approval (PMA) of Birmingham Hip Resurfacing (BHR) System &#8211; P040033</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/07/despite-the-reasons-against-fda-advisory-panel-recommends-conditional-approval-of-smith-nephews-birmingham-hip-resurfacing-technology/" target="_blank">Despite the Reasons AGAINST &#8211; FDA Advisory Panel Recommends Conditional Approval of Smith &amp; Nephew&#8217;s BIRMINGHAM HIP Resurfacing Technology</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/07/p040033-birmingham-hip-resurfacing-bhr-system-by-smithnephew-orthopaedics-fdazilla-devices/" target="_blank">P040033: BIRMINGHAM HIP RESURFACING (BHR) SYSTEM by SMITH&amp;NEPHEW ORTHOPAEDICS &#8211; FDAzilla Devices</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/07/www-fda-govohrmsdocketsdockets05p044005p-0440-c000001-01-vol2-pdf/" target="_blank">Smith &amp; Nephew&#8217;s :Response to Wright Medical Technology&#8217;s Citizen&#8217;s Petition to Deny PPrIA P040033</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/07/post-approval-studies-for-smith-nephew-bhr-not-useful/" target="_blank">Post-Approval Studies for Smith &amp; Nephew BHR &#8211; NOT USEFUL</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/07/wright-medicals-response-to-smith-nephews-response-to-wmt-request-to-deny-bhr-pma/" target="_blank">Wright Medical&#8217;s Response to Smith &amp; Nephew&#8217;s Response to WMT request to Deny BHR PMA</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/07/attachments-to-wright-medicals-request-to-deny-pma-to-smith-nephew-bhr/" target="_blank">Attachments to Wright Medical&#8217;s request to Deny PMA to Smith &amp; Nephew BHR</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/06/17/fda-pma-how-this-hides-the-guilty-and-stops-the-damaged-and-suffering-from-getting-justice-smith-nephew/" target="_blank">FDA PMA &#8211; how this hides the guilty and stops The Damaged and Suffering from getting Justice &#8211; Smith &amp; Nephew</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/07/07/smith-nephew-bhr-pma-first-of-a-kind-pma-who-pulled-what-strings/" target="_blank">Smith &amp; Nephew &#8211; BHR PMA &#8211; FIRST OF A KIND PMA &#8211; WHO PULLED WHAT STRINGS????</a> (earlsview.com)</li>
</ul><br />Filed under: <a href='/category/510k-process/'>510k process</a>, <a href='/category/birmingham-hip-resurfacing/'>Birmingham Hip Resurfacing</a>, <a href='/category/smith-nephew/'>Smith &amp; Nephew</a>, <a href='/category/smith-nephew-bhr-problems/'>Smith &amp; Nephew BHR Problems</a> Tagged: <a href='/tag/constraint/'>Constraint</a>, <a href='/tag/fda/'>FDA</a>, <a href='/tag/federal-food-drug-and-cosmetic-act/'>Federal Food Drug and Cosmetic Act</a>, <a href='/tag/food-drug-administration/'>Food &amp; Drug Administration</a>, <a href='/tag/hip-resurfacing/'>hip resurfacing</a>, <a href='/tag/medical-device/'>Medical device</a>, <a href='/tag/nephewsmith/'>NephewSmith</a>, <a href='/tag/premarket-approval/'>Premarket Approval</a>, <a href='/tag/smith-nephew/'>Smith &amp; Nephew</a>, <a href='/tag/united-states/'>UNited States</a> <a rel="nofollow" href="http://feeds.wordpress.com/1.0/gocomments/earlstevens58.wordpress.com/7521/"><img alt="" border="0" src="http://feeds.wordpress.com/1.0/comments/earlstevens58.wordpress.com/7521/" /></a> <img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=7521&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></content:encoded>
			<wfw:commentRss>https://earlsview.com/2012/07/08/smith-nephew-bhr-food-and-drug-administration-hhs/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/6b9f08d281cf2be916ed45fc4fe2ecd7?#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">earlstevens58</media:title>
		</media:content>
	</item>
		<item>
		<title>Gynecare Prolift Mesh Sold by J&amp;J Without FDA Approval &#124; InjuryBoard Fort Worth</title>
		<link>https://earlsview.com/2012/03/24/gynecare-prolift-mesh-sold-by-jj-without-fda-approval-injuryboard-fort-worth/</link>
		<comments>https://earlsview.com/2012/03/24/gynecare-prolift-mesh-sold-by-jj-without-fda-approval-injuryboard-fort-worth/#comments</comments>
		<pubDate>Fri, 23 Mar 2012 23:10:00 +0000</pubDate>
		<dc:creator><![CDATA[earlstevens58]]></dc:creator>
				<category><![CDATA[510k process]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Vaginal Mesh]]></category>
		<category><![CDATA[Ethicon]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Federal Food Drug and Cosmetic Act]]></category>
		<category><![CDATA[Food & Drug Administration]]></category>
		<category><![CDATA[Fort Worth Texas]]></category>
		<category><![CDATA[Johnson]]></category>
		<category><![CDATA[lawsuit]]></category>
		<category><![CDATA[Prolapse]]></category>

		<guid isPermaLink="false">https://earlsview.com/?p=6598</guid>
		<description><![CDATA[Gynecare Prolift Mesh Sold by J&#38;J Without FDA Approval &#124; InjuryBoard Fort Worth. Gynecare Prolift Mesh Sold by J&#38;J Without &#8230;<p><a href="/2012/03/24/gynecare-prolift-mesh-sold-by-jj-without-fda-approval-injuryboard-fort-worth/">Continue reading &#187;</a></p><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=6598&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
				<content:encoded><![CDATA[<p><a href="http://fortworth.injuryboard.com/medical-devices-and-implants/gynecare-prolift-mesh-sold-by-jj-without-fda-approval.aspx?googleid=299246">Gynecare Prolift Mesh Sold by J&amp;J Without FDA Approval | InjuryBoard Fort Worth</a>.</p>
<h1>Gynecare Prolift Mesh Sold by J&amp;J Without FDA Approval</h1>
<div class="attorneyboxes">
<div class="attorneyButtons"></div>
<div class="attorneyThumb"><a href="http://members.injuryboard.org/Shezad-Malik-MD-JD/"><img src="http://www.ibstatic2.com/ProfilePics/456707016734GBC_SThumbnail.jpg" alt="Shezad Malik MD JD" /></a></div>
<div class="attorneyNavy">
<div class="attorneyName"><a href="http://members.injuryboard.org/Shezad-Malik-MD-JD/">Shezad Malik MD JD</a></div>
</div>
<div class="attorneyText">Attorney<br />
<strong>(888) 210-9693</strong></div>
</div>
<p><span class="blogAuthor"> Posted by <a href="http://members.injuryboard.org/Shezad-Malik-MD-JD/">Shezad Malik MD JD</a></span><span class="blogDate">March 21, 2012 7:36 PM</span></p>
<p>According to a report by <a class="zem_slink" title="Bloomberg Television" href="http://www.bloomberg.com/tv/" rel="homepage" target="_blank">Bloomberg News</a>, <a class="zem_slink" title="Johnson &amp; Johnson" href="http://maps.google.com/maps?ll=40.498504,-74.44356&amp;spn=0.01,0.01&amp;q=40.498504,-74.44356%20%28Johnson%20%26%20Johnson%29&amp;t=h" rel="geolocation" target="_blank">Johnson &amp; Johnson</a> sold their Gynecare Prolift mesh for several years before obtaining <a class="zem_slink" title="Food and Drug Administration" href="http://maps.google.com/maps?ll=39.0353363,-76.9830894&amp;spn=0.01,0.01&amp;q=39.0353363,-76.9830894%20%28Food%20and%20Drug%20Administration%29&amp;t=h" rel="geolocation" target="_blank">FDA approval</a>. Johnson &amp; Johnson has been subjected to <a class="zem_slink" title="Product liability" href="http://en.wikipedia.org/wiki/Product_liability" rel="wikipedia" target="_blank">product liability</a> lawsuits brought by women who suffered complications allegedly caused by design defects with the <a class="zem_slink" title="Vagina" href="http://en.wikipedia.org/wiki/Vagina" rel="wikipedia" target="_blank">vaginal</a> surgical mesh.</p>
<p>Johnson &amp; Johnson’s Ethicon unit began selling the Prolift mesh in March 2005, but it was not approved by the FDA until May 2008.</p>
<p>Johnson &amp; Johnson sold the Gynecare Prolift mesh without approval, and claimed that it was substantially similar to the Gynecare Gynemesh, which was already on the market.</p>
<p><img style="height:242px;float:left;" src="http://fortworth.injuryboard.com/uploadedimages/InjuryBoardcom_Content/Blogs/Regional_Blogs/Ethicon_Gynecare_Transvaginal_Mesh_Lawsuits%281%29.jpg" alt="" />The Ethicon Gynecare Prolift mesh is one of a number of surgical mesh products manufactured by Johnson &amp; Johnson, that are the subject product liability lawsuits nationwide.</p>
<p><strong>Thousand of <a class="zem_slink" title="Lawsuit" href="http://en.wikipedia.org/wiki/Lawsuit" rel="wikipedia" target="_blank">Lawsuits</a></strong></p>
<p>Thousands of women are filing lawsuits, claiming that they suffered painful and debilitating complications after the vaginal mesh was implanted, such as pelvic pain, infection and erosion of the mesh through the vagina.</p>
<p>All vaginal mesh lawsuits involve similar allegations that the manufacturers failed to adequately research and test their products. Furthermore they claim, rushing the products to the market through the FDA’s controversial fast-track approval system, known as the <a class="zem_slink" title="Federal Food, Drug, and Cosmetic Act" href="http://en.wikipedia.org/wiki/Federal_Food%2C_Drug%2C_and_Cosmetic_Act" rel="wikipedia" target="_blank">510 (k)</a> process, which allows the agency to approve medical devices without rigorous pre-market testing when they feature a substantially similar design to other previously approved products.</p>
<p><strong>FDA 510 (k) Process</strong></p>
<p>Johnson &amp; Johnson reportedly failed to obtain 510(k) approval before marketing the Gynecare Prolift mesh.</p>
<p><strong>FDA Warning</strong></p>
<p>In July 2011, the FDA issued transvaginal mesh warning, indicating that they have been unable to find any evidence that transvaginal mesh kits used for repair of <a class="zem_slink" title="Prolapse" href="http://en.wikipedia.org/wiki/Prolapse" rel="wikipedia" target="_blank">pelvic organ prolapse</a> provide any benefit over other available means of treatment.</p>
<h6 class="zemanta-related-title" style="font-size:1em;">Related articles</h6>
<ul class="zemanta-article-ul">
<li class="zemanta-article-ul-li"><a href="http://ducknetweb.blogspot.com/2012/03/j-and-j-sold-vaginal-mesh-implant.html" target="_blank">J and J Sold Vaginal Mesh Implant Without FDA Approval for 3 Years</a> (ducknetweb.blogspot.com)</li>
<li class="zemanta-article-ul-li"><a href="http://fdarecalls.wordpress.com/2012/02/28/february-272012-vaginal-mesh-news-for-ga-and-fl/" target="_blank">February 27,2012 Vaginal Mesh News for GA and FL</a> (fdarecalls.wordpress.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/03/14/consumer-reports-taps-ire-over-bad-medical-devices/" target="_blank">Consumer Reports taps ire over bad medical devices</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/01/07/fda-probes-jnj-bard-and-others-on-transvaginal-mesh-risks-massdevice-medical-device-industry-news/" target="_blank">FDA probes JNJ, Bard and others on transvaginal mesh risks | MassDevice &#8211; Medical Device Industry News</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/12/24/recalled-depuy-asr-hip-implant-lawsuits-filed-by-the-law-offices-of-john-david-hart-thestreet/" target="_blank">Recalled DePuy ASR Hip Implant Lawsuits Filed By The Law Offices Of John David Hart &#8211; TheStreet</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/01/14/johnson-johnson-hit-with-fda-warning-letter-massdevice-medical-device-industry-news/" target="_blank">Johnson &amp; Johnson hit with FDA warning letter | MassDevice &#8211; Medical Device Industry News</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/02/16/6414/" target="_blank">J&amp;J DePuy &#8211; Hip Implant that U.S. Rejected Was Sold Overseas</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="http://vaginalmeshcomplications.typepad.com/blog/2012/03/surgical-mesh-device-reclassified-to-be-qualified.html" target="_blank">Surgical Mesh Device Reclassified To Be Qualified</a> (vaginalmeshcomplications.typepad.com)</li>
<li class="zemanta-article-ul-li"><a href="/2012/03/07/howard-sadwins-suffering-from-metal-on-metal-hip-implant-mesh-medical-device-newsdesk/" target="_blank">Howard Sadwin&#8217;s Suffering from Metal-on-Metal Hip Implant | Mesh Medical Device Newsdesk</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="http://drugstoresource.wordpress.com/2012/03/23/hip-device-phaseout-followed-fda-data-request-new-york-times/" target="_blank">Hip Device Phaseout Followed FDA Data Request &#8211; New York Times</a> (drugstoresource.wordpress.com)</li>
</ul><br />Filed under: <a href='/category/510k-process/'>510k process</a>, <a href='/category/johnson-johnson/'>Johnson &amp; Johnson</a>, <a href='/category/vaginal-mesh/'>Vaginal Mesh</a> Tagged: <a href='/tag/ethicon/'>Ethicon</a>, <a href='/tag/fda/'>FDA</a>, <a href='/tag/federal-food-drug-and-cosmetic-act/'>Federal Food Drug and Cosmetic Act</a>, <a href='/tag/food-drug-administration/'>Food &amp; Drug Administration</a>, <a href='/tag/fort-worth-texas/'>Fort Worth Texas</a>, <a href='/tag/johnson/'>Johnson</a>, <a href='/tag/lawsuit/'>lawsuit</a>, <a href='/tag/prolapse/'>Prolapse</a> <a rel="nofollow" href="http://feeds.wordpress.com/1.0/gocomments/earlstevens58.wordpress.com/6598/"><img alt="" border="0" src="http://feeds.wordpress.com/1.0/comments/earlstevens58.wordpress.com/6598/" /></a> <img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=6598&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></content:encoded>
			<wfw:commentRss>https://earlsview.com/2012/03/24/gynecare-prolift-mesh-sold-by-jj-without-fda-approval-injuryboard-fort-worth/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/6b9f08d281cf2be916ed45fc4fe2ecd7?#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">earlstevens58</media:title>
		</media:content>

		<media:content url="http://www.ibstatic2.com/ProfilePics/456707016734GBC_SThumbnail.jpg" medium="image">
			<media:title type="html">Shezad Malik MD JD</media:title>
		</media:content>

		<media:content url="http://fortworth.injuryboard.com/uploadedimages/InjuryBoardcom_Content/Blogs/Regional_Blogs/Ethicon_Gynecare_Transvaginal_Mesh_Lawsuits%281%29.jpg" medium="image" />
	</item>
		<item>
		<title>Reforming the 510(k) Process: Where We Are, How We Got Here, and What’s to Come &#124; MDDI Medical Device and Diagnostic Industry News Products and Suppliers</title>
		<link>https://earlsview.com/2012/01/07/reforming-the-510k-process-where-we-are-how-we-got-here-and-whats-to-come-mddi-medical-device-and-diagnostic-industry-news-products-and-suppliers/</link>
		<comments>https://earlsview.com/2012/01/07/reforming-the-510k-process-where-we-are-how-we-got-here-and-whats-to-come-mddi-medical-device-and-diagnostic-industry-news-products-and-suppliers/#comments</comments>
		<pubDate>Fri, 06 Jan 2012 23:16:56 +0000</pubDate>
		<dc:creator><![CDATA[earlstevens58]]></dc:creator>
				<category><![CDATA[510k process]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[FDA 510k process]]></category>
		<category><![CDATA[FDA Recall]]></category>
		<category><![CDATA[FDA Review]]></category>
		<category><![CDATA[FDA Warning]]></category>
		<category><![CDATA[Center for Devices and Radiological Health]]></category>
		<category><![CDATA[Federal Food Drug and Cosmetic Act]]></category>
		<category><![CDATA[Food & Drug Administration]]></category>
		<category><![CDATA[Institute of Medicine]]></category>
		<category><![CDATA[Johnson]]></category>
		<category><![CDATA[Medical device]]></category>
		<category><![CDATA[UNited States]]></category>

		<guid isPermaLink="false">https://earlsview.com/?p=6149</guid>
		<description><![CDATA[Reforming the 510(k) Process: Where We Are, How We Got Here, and What’s to Come &#124; MDDI Medical Device and &#8230;<p><a href="/2012/01/07/reforming-the-510k-process-where-we-are-how-we-got-here-and-whats-to-come-mddi-medical-device-and-diagnostic-industry-news-products-and-suppliers/">Continue reading &#187;</a></p><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=6149&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
				<content:encoded><![CDATA[<p><a href="http://www.mddionline.com/article/reforming-510k-process-where-we-are-how-we-got-here-and-what%E2%80%99s-come">Reforming the 510(k) Process: Where We Are, How We Got Here, and What’s to Come | MDDI Medical Device and Diagnostic Industry News Products and Suppliers</a>.</p>
<div id="publish-info">Published: January 5, 2012</div>
<div id="article_title"></div>
<div>Reforming the 510(k) Process: Where We Are, How We Got Here, and What’s to Come</div>
<div></div>
<div id="author">By: Chris Henza and Geoff Hutchins</p>
<div class="like-share"><span class="fbshare"><br />
</span></div>
</div>
<h2>The Need for Change</h2>
<p><a href="http://www.mddionline.com/sites/www.mddionline.com/files/image/art/arrows.jpg"><img class="alignright" style="margin-left:7px;margin-right:7px;" src="http://www.mddionline.com/sites/www.mddionline.com/files/image/art/arrows.jpg" alt="arrows" width="300" height="225" align="right" hspace="7" /></a>To be marketed in the United States, medical devices must go through a regulatory process outlined by the <a class="zem_slink" title="Federal Food, Drug, and Cosmetic Act" href="http://en.wikipedia.org/wiki/Federal_Food%2C_Drug%2C_and_Cosmetic_Act" rel="wikipedia">Federal Food, Drug, and Cosmetic Act</a> (FFDCA)<sup>1</sup> and enforced by the <a class="zem_slink" title="Food and Drug Administration" href="http://www.fda.gov/" rel="homepage">U.S. Food and Drug Administration (FDA)</a><sup>2</sup>.  For most moderate risk medical devices, the path involves clearance through the 510(k) process, named for section 510(k)<sup>3</sup> of the FFDCA. In recent years, there has been dialogue between patients, healthcare providers, and policymakers in regards to the 510(k) process and the safety and efficacy of medical devices on the market. Additionally, with global pressures to innovate and compete, U.S. device manufacturers are concerned that changes to the 510(k) process could delay new device market entry.</p>
<h2>The FDA Assessment</h2>
<p>In response to this dialog, FDA began an assessment of the 510(k) process in September 2009 to improve the program. A working group was charged to explore actions by FDA’s Centers for Devices &amp; Radiological Health (<a class="zem_slink" title="The Center for Democracy and Human Rights in Saudi Arabia" href="http://en.wikipedia.org/wiki/The_Center_for_Democracy_and_Human_Rights_in_Saudi_Arabia" rel="wikipedia">CDHR</a>). The working group was comprised of representatives from across the <a class="zem_slink" title="Center for Devices and Radiological Health" href="http://en.wikipedia.org/wiki/Center_for_Devices_and_Radiological_Health" rel="wikipedia">CDRH</a>, consisting of 10 subgroups assigned a particular focus within the broader 510(k) framework.</p>
<p>The working group focused on strengthening the program and improving consistency of its decision making, with the principal focus on actions the center could take in the short term under its existing statutory authority to evaluate the 510(k) process. To that end, the working group analyzed how the current process operated, what challenges it presented for CDRH staff and others, and<strong> w</strong>hat steps the center might take to improve the program. The report from the working group was issued in August 2010. The findings focused on three major areas:</p>
<ol>
<li>A rational, well-defined and consistently interpreted review standard.</li>
<li style="margin-bottom:.0001pt;">Well informed <a class="zem_slink" title="Decision making" href="http://en.wikipedia.org/wiki/Decision_making" rel="wikipedia">Decision Making</a>.</li>
<li style="margin-bottom:.0001pt;">Continuous <a class="zem_slink" title="Quality assurance" href="http://en.wikipedia.org/wiki/Quality_assurance" rel="wikipedia">Quality Assurance</a>.</li>
</ol>
<p>The working group has issued or is planning to issue the following:</p>
<ul>
<li>Draft guidance on changes to 510(k) cleared devices.</li>
<li>Draft guidance on the de novo process.</li>
<li>Draft “510(k) Paradigm” guidance.</li>
<li>Draft standards guidance.</li>
<li>Draft 510(k) transfer of ownership regulation.</li>
<li>“515 Program Initiative” to address all outstanding “preamendment” Class III device types subject to 510(k) review.</li>
<li>Total product life cycle database.</li>
</ul>
<h2>The IOM Response</h2>
<p>FDA asked for input from the Institute of Medicine (IOM), which focused its review on whether the current 510(k) process protects patients, promotes innovation, and If not, what legislative, regulatory, or administrative changes are recommended to best achieve the goals of the 510(k) process.</p>
<p>In July 2011, the IOM issued its findings that the current 510(k) process does not determine safety or efficacy, lacks the legal basis to screen for safety and efficacy, and furthermore, was never intended to do either. In the area of innovation, the IOM found the process does not require a device to be innovative and does not reward innovation, but can play a role in facilitating innovation by making devices available in a timely manner.</p>
<p>The IOM recommended “rather than continuing to modify the 35-year-old 510(k) process, the IOM concludes that the FDA’s finite resources would be better invested in developing an integrated premarket and postmarket regulatory framework.”<sup>4</sup></p>
<h2>Next Steps by the FDA</h2>
<p>While none of the IOM’s recommendations are binding, FDA announced that it will open a public docket in July 2011 to begin receiving public comments on the IOM’s report on the 510(k) program. At the same time, FDA defended its decision to modify the current process rather than start from scratch as the IOM recommended, saying “the 510(k) process should not be eliminated but FDA is open to additional proposals and approaches for continued improvement of our device review program.”<sup>5</sup></p>
<p>FDA has continued to move forward with its own plan to reform the 510(k) process as outlined in the 510(k) Preliminary Report.<sup>6</sup> The main elements of the FDA’s approach are:</p>
<ul>
<li>Create new or update existing guidances for clarity.</li>
<li>Integrate systems and databases to make information more accessible.</li>
<li>Issue regulation to cover previously neglected items [such as reclassified devices (515 Program Initiative) and transfer of ownership of a 510(k)].</li>
</ul>
<h2 class="rtecenter"><a href="http://www.mddionline.com/sites/www.mddionline.com/files/image/art/figure-1.gif"><img class="aligncenter" src="http://www.mddionline.com/sites/www.mddionline.com/files/image/art/figure-1.gif" alt="Figure 1: Regulatory Reform Timeline" width="600" height="295" /></a></h2>
<h2>Current <a class="zem_slink" title="State of Change" href="http://en.wikipedia.org/wiki/State_of_Change" rel="wikipedia">State of Change</a></h2>
<p><strong>New Guidance: Changes to 510(k) products.</strong> The new draft guidance eliminates the flow chart, one of the industries most used tools. Additionally, comparisons of a device can now only be made to previously cleared versions of that device. When device changes require the manufacturer to submit a 510(k) for a change, they are to use the previously cleared version of the device for the predicate. Previously, if they were to submit a new 510(k) they could use any cleared device for the predicate. Another change is that the new guidance does not allow limiting the indications for any reason beyond marketing or it will be considered a substantial change. Lastly, the new guidance added a section on manufacturing process change.</p>
<p><strong>New Guidance: De Novo Process</strong>. Besides the original <a class="zem_slink" title="De novo" href="http://en.wikipedia.org/wiki/De_novo" rel="wikipedia">De novo</a> request after Not Substantially Equivalent (NSE) pathway, the new draft guidance creates a second pathway, Pre de novo submission followed by 510(k). The Pre de novo submission brings the FDA in from the beginning, instead of after NSE, which many companies with innovative products were already doing. Device makers will likely benefit from the new pathway, because the defined process will no doubt enhance communication between industry and regulators.</p>
<p>In addition to the new pathway, the new guidance provides greater definition and more fully explains the FDA review process. These changes suggest a more consistent result for future submissions.</p>
<p><strong>515 Program Initiative.</strong> When FDA’s medical device regulation program began in the late 1970s, FDA regulated over 100 Class III device types through the 510(k) program. The intent was that FDA’s regulation would be temporary and that over time, FDA would decide to reclassify those device types (or regulations) into Class I or II, or to sustain the classification in Class III and call for PMA applications.<sup>7</sup></p>
<p>As of 2009, 26 out of 100 medical device regulations remained in the transitional state of class III designated 510(k) pending reclassification. In late 2009, FDA kicked off the 515 Program Initiative to facilitate the final adjudication of these remaining Class III device types with targeted completion end of 2012.<sup>7</sup></p>
<p>An example of one of the 26 device types is pacemaker programmers, classified under 21 CFR 870.3700, and with product code KRG.</p>
<h2>Total Product Life Cycle (TPLC)</h2>
<p>The TPLC<sup>8</sup> database combines data to present an integrated record of premarket and postmarket activity for medical devices. The databases included in TPLC:</p>
<ul>
<li>Premarket Approvals (PMA).</li>
<li>Premarket Notifications (510(k)s).</li>
<li>MAUDE (Manufacturer and User Facility Device Experience).</li>
<li>Recalls of Medical Devices.</li>
<li>Device Classification.</li>
</ul>
<p>The TPLC database integrates data by product code, so only datasets containing a procode are included in the TPLC database. The TPLC reports include counts of the database information (i.e. number of recalls, number of premarket submissions). Details about which events were counted are available through links on the pages. As the various data sources are updated or refreshed, these counts may change.</p>
<p>Manufacturer names continue to provide a challenge. Firm names are subject to changes, and it’s not unusual to find inconsistent spelling or abbreviations in the MAUDE database. To aggregate the information in the TPLC, all firm names have been simplified and consolidated. As the data in MAUDE improves, firm names will become the firm name in the registration database as well.</p>
<table width="600" border="0" cellspacing="1" cellpadding="1" align="center">
<tbody>
<tr>
<td><a href="http://www.mddionline.com/sites/www.mddionline.com/files/image/art/figure-2.gif"><img class="aligncenter" src="http://www.mddionline.com/sites/www.mddionline.com/files/image/art/figure-2.gif" alt="" width="600" height="600" /></a></td>
</tr>
<tr>
<td><span style="font-size:smaller;"><strong>Figure 2: This is a screenshot of a TPLC report for cable electrodes. Cable electrodes are 510(k) exempt, which is why the “premarket reviews” section is brief. </strong></span></td>
</tr>
</tbody>
</table>
<h2>510(k) Paradigm Guidance</h2>
<p>On December 27th the FDA released “The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]” that according to the table Accomplishments: CDRH Plan of Action for 510(k) and Science10 fulfills their intent to provide a draft 510(k) Paradigm Guidance.<sup>9</sup></p>
<p>Given that the vast majority of medical devices come to market through the 510(k) process, changes to this process are the most impactful for the industry. The draft guidance provides greater clarity regarding both the process of equivalence determination and the expected content for a 510(k). The guidance also specifies that the FDA intends to verify the content of a 510(k) summary for accuracy and completeness and will require updates if further information is submitted for review.</p>
<p>Appendix B is devoted to defining the requirements of the 510(k) summary.</p>
<p>The draft guidance addresses many of the industry’s concerns regarding the 510(k) process, mainly the lack of predictability and transparency. The process of determining substantial equivalence (or not) is detailed step by step in the body of the draft document, including specific examples, then pulled together via flowchart in appendix A, which includes reference back to both the relevant section of the draft document and to the applicable regulation. The draft document explains the appropriate use of multiple predicates, introduces a new term “reference device”, and establishes principles for determining new intended use.</p>
<p>Another commonly expressed concern is that companies are unclear when the FDA will require clinical data for submissions. According to section IV.F, the FDA uses a “stepwise analytical approach” to showing equivalency: descriptive information is considered first, then non-clinical performance testing, then clinical testing when other data is insufficient to show equivalence. Although this information is vague, there are several examples included that demonstrate instances when the FDA might request clinical data.</p>
<p>By documenting the process in such a descriptive way, this draft guidance allows industry insight into what the reviewers are looking for and will hopefully provide for a reduction in the amount of requests for more information received by the industry.</p>
<h2>Anticipated Steps</h2>
<p><strong>Standards Guidance. </strong>The standards guidance is intended to provide clarity and consistency in the application of standards. The release date is unknown.</p>
<p><strong>Draft 510(k) transfer of ownership regulation</strong>. Currently the FDA is not involved in transfers of ownership; a 510(k) may be bought, sold, or transferred by companies.11 Due to lack of official documentation, the buyer obtains a warranty from the seller that the seller owns the 510(k) and has not previously sold / transferred it to another party. Inadequate record keeping can cause legal issues. The purpose of the new regulation is to better document 510(k) transfers of ownership. The recommendation from the 510(k) working group was that the center should update its 510(k) database in a timely manner when a transfer of ownership occurs.12 currently, the 510(k) database reflects who submitted the 510(k) initially, and this inaccuracy is perpetuated by the TPLC report.</p>
<p>The release date is expected shortly.</p>
<h2>The FDA and Innovation</h2>
<p>The FDA has launched an Innovation Initiative<sup>13</sup> in response to concerns from the medical device industry that modifications to the 510(k) process would negatively impact innovation because of increased time and cost as well as the need for time-intensive clinical evaluation. The Innovation Pathway<sup>14</sup> is a priority review program for new, breakthrough medical devices and is intended to strengthen the nation’s research infrastructure for developing breakthrough technologies and advancing quality regulatory science.</p>
<h2>The Future: Reading the Tea Leaves</h2>
<p>Given the release of the “The 510(k) Program” document it is clear that the FDA is standing firmly behind the 510(k) process and is committed to its ongoing improvement. Although the released guidances are in draft form, we anticipate that the FDA will apply these guidances immediately.</p>
<p>As time unfolds, we expect this reform to have the following impact:</p>
<ul>
<li>  A higher standard for the selection of the predicate device.</li>
<li>A higher standard for claiming substantial equivalence.</li>
<li>Limitation on the use of split predicates and multiple predicates.</li>
<li>Greater use of the de novo process.</li>
<li>Higher probability of a “Not Substantial Equivalent” determination.</li>
<li>Greater consistence and predictability of the process.</li>
<li>The FDA’s willingness to continually review and improve the 510(k) process is a critical part of its ongoing mission to provide American patients with safety, efficacy and innovation in medical devices.</li>
</ul>
<p><strong><span style="font-size:11pt;">References:</span></strong></p>
<div style="margin-left:.25in;"><span style="font-size:smaller;">1.<span style="font:7pt 'Times New Roman';">     </span></span><a href="http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/default.htm" target="_blank"><span style="font-size:smaller;">http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/default.htm</span></a></div>
<div style="margin-left:.25in;text-indent:-.25in;"><span style="font-size:smaller;">2.<span style="font:7pt 'Times New Roman';">     </span></span><a href="http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPartFrom=800&amp;CFRPartTo=1299" target="_blank"><span style="font-size:smaller;">http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPartFrom=800&amp;CFRPartTo=1299</span></a></div>
<div style="margin-left:.25in;text-indent:-.25in;"><span style="font-size:smaller;">3.<span style="font:7pt 'Times New Roman';">     </span></span><a href="http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/FDCActChapterVDrugsandDevices/ucm109201.htm" target="_blank"><span style="font-size:smaller;">http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/FDCActChapterVDrugsandDevices/ucm109201.htm</span></a></div>
<div style="margin-left:.25in;text-indent:-.25in;"><span style="font-size:smaller;"><span style="text-decoration:none;">4.<span style="font:7pt 'Times New Roman';">     </span></span></span><a href="http://www.iom.edu/Reports/2011/Medical-Devices-and-the-Publics-Health-The-FDA-510k-Clearance-Process-at-35-Years/Press-Release.aspx" target="_blank"><span style="font-size:smaller;">http://www.iom.edu/Reports/2011/Medical-Devices-and-the-Publics-Health-The-FDA-510k-Clearance-Process-at-35-Years/Press-Release.aspx</span></a></div>
<div style="margin-left:.25in;text-indent:-.25in;"><span style="font-size:smaller;">5.<span style="font:7pt 'Times New Roman';">     </span></span><a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm265908.htm" target="_blank"><span style="font-size:smaller;">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm265908.htm</span></a></div>
<div style="margin-left:.25in;text-indent:-.25in;"><span style="font-size:smaller;">6.<span style="font:7pt 'Times New Roman';">     </span></span><a href="http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM220784.pdf" target="_blank"><span style="font-size:smaller;">http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM220784.pdf</span></a></div>
<div style="margin-left:.25in;text-indent:-.25in;"><span style="font-size:smaller;"><span style="text-decoration:none;">7.<span style="font:7pt 'Times New Roman';">     </span></span></span><a href="http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHTransparency/ucm240310.htm" target="_blank"><span style="font-size:smaller;">http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHTransparency/ucm240310.htm</span></a></div>
<div style="margin-left:.25in;text-indent:-.25in;"><span style="font-size:smaller;"><span style="text-decoration:none;">8.<span style="font:7pt 'Times New Roman';">     </span></span></span><a href="http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTPLC/tplc.cfm" target="_blank"><span style="font-size:smaller;">http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTPLC/tplc.cfm</span></a></div>
<div style="margin-left:.25in;text-indent:-.25in;"><span style="font-size:smaller;"><span style="text-decoration:none;">9.<span style="font:7pt 'Times New Roman';">     </span></span></span><a href="http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm282958.htm" target="_blank"><span style="font-size:smaller;">http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm282958.htm</span></a></div>
<div style="margin-left:.25in;text-indent:-.25in;"><span style="font-size:smaller;"><span style="text-decoration:none;">10. </span></span><a href="http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPartFrom=800&amp;CFRPartTo=1299" target="_blank"><span style="font-size:smaller;">http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHReports/ucm276286.htm</span></a></div>
<div style="margin-left:.25in;text-indent:-.25in;"><span style="font-size:smaller;">11. </span><a href="http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm150086.htm#5k" target="_blank"><span style="font-size:smaller;">http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm150086.htm#5k</span></a></div>
<div style="margin-left:.25in;text-indent:-.25in;"><span style="font-size:smaller;">12. </span><a href="http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHReports/UCM239450.pdf" target="_blank"><span style="font-size:smaller;">http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHReports/UCM239450.pdf</span></a></div>
<div style="margin-left:.25in;text-indent:-.25in;"><span style="font-size:smaller;">13. </span><a href="http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHInnovation/default.htm" target="_blank"><span style="font-size:smaller;">http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHInnovation/default.htm</span></a></div>
<div style="margin-left:.25in;"><span style="font-size:smaller;">14. </span><a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm242629.htm" target="_blank"><span style="font-size:smaller;">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm242629.htm</span></a></div>
<p><em>Chris Henza is a regulatory affairs specialist with Regulatory Compliance Associates Inc. Geoff Hutchins is a senior program director, medical devices with Regulatory Compliance Associates, Inc.<br />
</em></p>
<h6 class="zemanta-related-title" style="font-size:1em;">Related articles</h6>
<ul class="zemanta-article-ul">
<li class="zemanta-article-ul-li"><a href="/2011/12/17/howard-sdwin-what-isnt-being-published-is-the-truth-regarding-the-medical-device-world/">Howard Sdwin: What isn&#8217;t being published is the truth regarding the medical device world</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/12/20/fda-seeks-to-include-more-women-in-medical-device-trials/">FDA seeks to include more women in medical device trials</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="http://www.diabetesdaily.com/farrell/2011/09/20/getting-fda-information/">Getting FDA information</a> (diabetesdaily.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/12/16/bill-would-require-more-monitoring-of-implants-nytimes-com/">Bill Would Require More Monitoring of Implants &#8211; NYTimes.com</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/09/14/jj-led-vaginal-mesh-group-says-fda-should-require-more-studies/">J&amp;J-Led Vaginal Mesh Group Says FDA Should Require More Studies</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="http://thebovine.wordpress.com/2012/01/06/fda-at-a-crossroads-conference/">&#8220;FDA at a Crossroads&#8221; conference</a> (thebovine.wordpress.com)</li>
<li class="zemanta-article-ul-li"><a href="http://www.prweb.com/releases/prweb2012/1/prweb9078973.htm">&#8220;FDA, You Were Wrong!&#8221;, a Timely Story Documenting the Impact of Government Regulations upon the General Public is Released by Dr. Robert Christensen</a> (prweb.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/12/24/recalled-depuy-asr-hip-implant-lawsuits-filed-by-the-law-offices-of-john-david-hart-thestreet/">Recalled DePuy ASR Hip Implant Lawsuits Filed By The Law Offices Of John David Hart &#8211; TheStreet</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="http://blogs.windriver.com/wind_river_blog/2011/09/by-santhosh-nair-in-september-of-2009-the-fda-commissioned-an-independent-committee-review-of-its-510k-process-the-most-c.html">Somewhere Between IOM and FDA Lies a New 510(k) Process</a> (blogs.windriver.com)</li>
<li class="zemanta-article-ul-li"><a href="http://www.mobilestorm.com/resources/digital-marketing-blog/fda-issues-draft-guidelines-for-healthcare-social-media-marketing/">FDA Issues Draft Guidelines for Healthcare Social Media Marketing</a> (mobilestorm.com)</li>
</ul><br />Filed under: <a href='/category/510k-process/'>510k process</a>, <a href='/category/fda/'>FDA</a>, <a href='/category/fda-510k-process/'>FDA 510k process</a>, <a href='/category/fda-recall/'>FDA Recall</a>, <a href='/category/fda-review-2/'>FDA Review</a>, <a href='/category/fda-warning/'>FDA Warning</a> Tagged: <a href='/tag/center-for-devices-and-radiological-health/'>Center for Devices and Radiological Health</a>, <a href='/tag/fda/'>FDA</a>, <a href='/tag/federal-food-drug-and-cosmetic-act/'>Federal Food Drug and Cosmetic Act</a>, <a href='/tag/food-drug-administration/'>Food &amp; Drug Administration</a>, <a href='/tag/institute-of-medicine/'>Institute of Medicine</a>, <a href='/tag/johnson/'>Johnson</a>, <a href='/tag/medical-device/'>Medical device</a>, <a href='/tag/united-states/'>UNited States</a> <a rel="nofollow" href="http://feeds.wordpress.com/1.0/gocomments/earlstevens58.wordpress.com/6149/"><img alt="" border="0" src="http://feeds.wordpress.com/1.0/comments/earlstevens58.wordpress.com/6149/" /></a> <img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=6149&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></content:encoded>
			<wfw:commentRss>https://earlsview.com/2012/01/07/reforming-the-510k-process-where-we-are-how-we-got-here-and-whats-to-come-mddi-medical-device-and-diagnostic-industry-news-products-and-suppliers/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/6b9f08d281cf2be916ed45fc4fe2ecd7?#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">earlstevens58</media:title>
		</media:content>

		<media:content url="http://www.mddionline.com/sites/www.mddionline.com/files/image/art/arrows.jpg" medium="image">
			<media:title type="html">arrows</media:title>
		</media:content>

		<media:content url="http://www.mddionline.com/sites/www.mddionline.com/files/image/art/figure-1.gif" medium="image">
			<media:title type="html">Figure 1: Regulatory Reform Timeline</media:title>
		</media:content>

		<media:content url="http://www.mddionline.com/sites/www.mddionline.com/files/image/art/figure-2.gif" medium="image" />
	</item>
		<item>
		<title>Howard Sdwin: What isn’t being published is the truth regarding the medical device world</title>
		<link>https://earlsview.com/2011/12/17/howard-sdwin-what-isnt-being-published-is-the-truth-regarding-the-medical-device-world/</link>
		<comments>https://earlsview.com/2011/12/17/howard-sdwin-what-isnt-being-published-is-the-truth-regarding-the-medical-device-world/#comments</comments>
		<pubDate>Fri, 16 Dec 2011 22:53:07 +0000</pubDate>
		<dc:creator><![CDATA[earlstevens58]]></dc:creator>
				<category><![CDATA[FDA]]></category>
		<category><![CDATA[FDA 510k process]]></category>
		<category><![CDATA[Metal on metal hip]]></category>
		<category><![CDATA[Metallosis]]></category>
		<category><![CDATA[Blumenthal]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Federal Food Drug and Cosmetic Act]]></category>
		<category><![CDATA[Food & Drug Administration]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hip]]></category>
		<category><![CDATA[Karen Riley]]></category>
		<category><![CDATA[Medical device]]></category>
		<category><![CDATA[UNited States]]></category>

		<guid isPermaLink="false">https://earlsview.com/?p=5890</guid>
		<description><![CDATA[What isn’t being published is the truth regarding the medical device world. by Howard Sadwin Howard&#8217;s Opinion: If we obtained &#8230;<p><a href="/2011/12/17/howard-sdwin-what-isnt-being-published-is-the-truth-regarding-the-medical-device-world/">Continue reading &#187;</a></p><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=5890&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
				<content:encoded><![CDATA[<h1>What isn’t being published is the truth regarding the <a class="zem_slink" title="Medical device" href="http://en.wikipedia.org/wiki/Medical_device" rel="wikipedia">medical device</a> world.</h1>
<p>by Howard Sadwin</p>
<h2>Howard&#8217;s Opinion:</h2>
<p><a href="http://earlstevens58.files.wordpress.com/2011/12/howard-sadwin.jpeg"><img class="alignleft size-full wp-image-5891" title="Howard Sadwin" src="http://earlstevens58.files.wordpress.com/2011/12/howard-sadwin.jpeg?w=529" alt=""   /></a>If we obtained data in <a class="zem_slink" title="The States" href="http://www.history.com/topics/states" rel="historycom">USA</a> re: <a class="zem_slink" title="Hip" href="http://en.wikipedia.org/wiki/Hip" rel="wikipedia">hips</a> 2004 – 2008, procedures, adversities reported to surgeons, <a class="zem_slink" title="Food and Drug Administration" href="http://www.fda.gov/" rel="homepage">FDA</a> etc. we could be better prepared  to deal with this disaster. Also enlighten people with all the FDAs new ideas and actions.</p>
<p>Unfortunately, the FDA neglects to face facts: there does not seem to be any control  of basics now and back in time regarding medical device manufacturers. All these new actions, new punishment, new data on devices, etc. if you paid for all the information enewsletters@fdanews.com it would cost me thousands of dollars and all I would be getting is proposed actions to be taken and under tight scrutiny of FDA a lot of paper,  when in reality it appears the medical device world dictates the rules.</p>
<p>By the time anyone can agree right and wrong and implementation of an established penalty system and an understanding of what the FDA is trying to say, a medical device could fail, be replaced by another, it could fail etc. on the good side there will be more success stories than failure stories.</p>
<p>I mentioned once before if you go through a red light, you pay a fine, go to jail or go to court, end of story if your medical device harms a <a class="zem_slink" title="Human" href="http://en.wikipedia.org/wiki/Human" rel="wikipedia">human being</a> because of the product, you pay a fine ( high enough to rattle the board of directors) and put a stop to the medical device world dictating the rules.</p>
<p>Mr. Blumenthal is a positive note for changing this system, however, monitoring these devices was a stipulation made in approval of some hip devices, why was this not acted upon when these same devices began hurting people, if <a class="zem_slink" title="Properly discontinuous action" href="http://en.wikipedia.org/wiki/Properly_discontinuous_action" rel="wikipedia">proper action</a> wasn’t implemented back then, how are they going to change the necessary actions to be taken against a device manufacturer when it fails ?</p>
<p>Why do we make things so difficult; what is the harm in publishing and broad casting the truth, “ If you have a metal on metal hip and are experiencing problems seek professional help”.</p>
<p>Repetition of this type of information will help a fair amount of people, as you know, and this is one of the most important things we can hope to accomplish quickly.</p>
<p>The comment in Barry’s article as spokeswoman for the FDA Karen Riley studies had shown that current <a class="zem_slink" title="Federal Food, Drug, and Cosmetic Act" href="http://en.wikipedia.org/wiki/Federal_Food%2C_Drug%2C_and_Cosmetic_Act" rel="wikipedia">510k</a> approval process was remarkably safe. I ask myself what is she basing her comment on?</p>
<p>People need to be informed about who runs the show,  the FDA or the medical device world . Getting new devices on the market is great the quicker the better, who is this better for <a class="zem_slink" title="Market share" href="http://en.wikipedia.org/wiki/Market_share" rel="wikipedia">Market Share</a> or humans?</p>
<h6 class="zemanta-related-title" style="font-size:1em;">Related articles</h6>
<ul class="zemanta-article-ul">
<li class="zemanta-article-ul-li"><a href="http://www.fda.gov/Safety/Recalls/ucm283879.htm">FDA Classifies Voluntary Physician Advisory Letter on Riata and Riata ST Silicone Defibrillation Leads as Class I Recall (URGENT MEDICAL DEVICE ADVISORY)</a> (fda.gov)</li>
<li class="zemanta-article-ul-li"><a href="http://www.medcitynews.com/2011/12/austen-bioinnovation-institute-fda-to-partner-on-medical-device-regulation/">Austen BioInnovation Institute, FDA to partner on medical device regulation</a> (medcitynews.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/12/16/bill-would-require-more-monitoring-of-implants-nytimes-com/">Bill Would Require More Monitoring of Implants &#8211; NYTimes.com</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="http://www.prweb.com/releases/prweb2011/12/prweb9045041.htm">Cosmetic Dermatology Center to Offer Cellulite and Contouring Treatments with Viora&#8217;s Reaction™, a Leading RF-Based Bi-Polar Medical Aesthetics Device</a> (prweb.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/08/14/sadwin-gets-to-the-heart-of-the-issues-with-fda-510k/">Sadwin gets to the heart of the Issues with FDA 510(k)</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="http://www.medcitynews.com/2011/12/st-jude-medical-hit-with-class-i-recall-for-faulty-defibrillator-leads/">St. Jude Medical hit with Class I recall for faulty defibrillator leads</a> (medcitynews.com)</li>
<li class="zemanta-article-ul-li"><a href="http://www.medcitynews.com/2011/12/handheld-brain-bleed-detector-gets-fda-approval/">Handheld brain bleed detector gets FDA approval</a> (medcitynews.com)</li>
<li class="zemanta-article-ul-li"><a href="http://www.prweb.com/releases/quickmedical/medicalsupplies/prweb9028565.htm">QuickMedical Introduces The Samaritan Pad Public Access Defibrillator</a> (prweb.com)</li>
<li class="zemanta-article-ul-li"><a href="http://www.medicalnewstoday.com/articles/239139.php">Stop Misbranding Lap-Band In Your Advertising, FDA Warns Companies</a> (medicalnewstoday.com)</li>
<li class="zemanta-article-ul-li"><a href="http://ducknetweb.blogspot.com/2011/12/doctor-in-oklahoma-gets-17-day-review.html">Doctor in Oklahoma Gets 17 Day Review and Approval for EZ Vein-Non Invasive Device To Help With Inserting IVs &amp; Finding the Veins</a> (ducknetweb.blogspot.com)</li>
</ul><br />Filed under: <a href='/category/fda/'>FDA</a>, <a href='/category/fda-510k-process/'>FDA 510k process</a>, <a href='/category/metal-on-metal-hip/'>Metal on metal hip</a>, <a href='/category/metallosis-2/'>Metallosis</a> Tagged: <a href='/tag/blumenthal/'>Blumenthal</a>, <a href='/tag/business/'>Business</a>, <a href='/tag/fda/'>FDA</a>, <a href='/tag/federal-food-drug-and-cosmetic-act/'>Federal Food Drug and Cosmetic Act</a>, <a href='/tag/food-drug-administration/'>Food &amp; Drug Administration</a>, <a href='/tag/healthcare/'>Healthcare</a>, <a href='/tag/hip-2/'>hip</a>, <a href='/tag/karen-riley/'>Karen Riley</a>, <a href='/tag/medical-device/'>Medical device</a>, <a href='/tag/united-states/'>UNited States</a> <a rel="nofollow" href="http://feeds.wordpress.com/1.0/gocomments/earlstevens58.wordpress.com/5890/"><img alt="" border="0" src="http://feeds.wordpress.com/1.0/comments/earlstevens58.wordpress.com/5890/" /></a> <img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=5890&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></content:encoded>
			<wfw:commentRss>https://earlsview.com/2011/12/17/howard-sdwin-what-isnt-being-published-is-the-truth-regarding-the-medical-device-world/feed/</wfw:commentRss>
		<slash:comments>11</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/6b9f08d281cf2be916ed45fc4fe2ecd7?#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">earlstevens58</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/12/howard-sadwin.jpeg" medium="image">
			<media:title type="html">Howard Sadwin</media:title>
		</media:content>
	</item>
		<item>
		<title>IOM chair discusses 510(k) report: origins, findings, response</title>
		<link>https://earlsview.com/2011/08/18/iom-chair-discusses-510k-report-origins-findings-response/</link>
		<comments>https://earlsview.com/2011/08/18/iom-chair-discusses-510k-report-origins-findings-response/#comments</comments>
		<pubDate>Thu, 18 Aug 2011 12:37:44 +0000</pubDate>
		<dc:creator><![CDATA[earlstevens58]]></dc:creator>
				<category><![CDATA[510k process]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[FDA 510k process]]></category>
		<category><![CDATA[FDA Recall]]></category>
		<category><![CDATA[FDA Review]]></category>
		<category><![CDATA[FDA Warning]]></category>
		<category><![CDATA[Institute of Medicine]]></category>
		<category><![CDATA[Federal Food Drug and Cosmetic Act]]></category>
		<category><![CDATA[Food & Drug Administration]]></category>
		<category><![CDATA[Hip Replacement]]></category>
		<category><![CDATA[Medical device]]></category>
		<category><![CDATA[Public health]]></category>
		<category><![CDATA[UNited States]]></category>
		<category><![CDATA[University of Florida]]></category>

		<guid isPermaLink="false">https://earlsview.com/?p=4852</guid>
		<description><![CDATA[IOM chair discusses 510(k) report: origins, findings, response Written by Brian Dunham   August 15, 2011 Source: Cardiovascular Business David &#8230;<p><a href="/2011/08/18/iom-chair-discusses-510k-report-origins-findings-response/">Continue reading &#187;</a></p><img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=4852&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></description>
				<content:encoded><![CDATA[<h3>IOM chair discusses <a class="zem_slink" title="Federal Food, Drug, and Cosmetic Act" href="http://en.wikipedia.org/wiki/Federal_Food%2C_Drug%2C_and_Cosmetic_Act" rel="wikipedia">510(k)</a> report: origins, findings, response</h3>
<p>Written by Brian Dunham   August 15, 2011 Source: <a href="http://www.cardiovascularbusiness.com/index.php?option=com_articles&amp;view=article&amp;id=29080" target="_blank">Cardiovascular Business</a></p>
<p><img src="http://www.cardiovascularbusiness.com/images/assets/Q2hhbGxvbmVyIHYyMjAxMS0wOC0xNiAwMTozMzo1Mg==.jpg" alt=" " width="200" align="left" border="0" hspace="0" vspace="0" /><em><a title="More news about::David R. Challoner" href="http://www.cardiovascularbusiness.com/_news/person/David+R.+Challoner">David R. Challoner</a>, MD, vice president for health affairs emeritus, <a title="More news about::University of Florida" href="http://www.cardiovascularbusiness.com/_news/organization/University+of+Florida">University of Florida</a> and chair of the <a title="More news about::Institute of Medicine" href="http://www.cardiovascularbusiness.com/_news/organization/Institute+of+Medicine">Institute of Medicine</a> (IOM) committee.</em><br />
<em> Image source: The National Academy of Sciences</em></p>
<p>The Institute of Medicine&#8217;s (IOM) recent recommendation to eliminate the <a title="More news about::510(k)" href="http://www.cardiovascularbusiness.com/_news/topic/510%28k%29">510(k)</a> clearance process for medical devices has prompted a sharp exchange between its leaders and medical device manufacturers.</p>
<p>The 510(k) clearance process allows medical devices to enter the market if manufacturers can demonstrate that a “substantial equivalent” is already in use. In an IOM report released in late <a href="http://www.cardiovascularbusiness.com/index.php?option=com_articles&amp;view=article&amp;id=28892:iom-to-fda-scrap-510k-start-fresh" target="_blank"><strong>July</strong></a>, a committee of 13 stated their unanimous opinion that the clearance process does not ensure medical device safety and effectiveness. The committee recommended creating a new framework for medical device approval.</p>
<p><a href="http://earlstevens58.files.wordpress.com/2011/08/institute-of-medicine3.jpg"><img class="alignright size-full wp-image-4853" title="Institute of Medicine" src="http://earlstevens58.files.wordpress.com/2011/08/institute-of-medicine3.jpg?w=529" alt=""   /></a>In an Aug. 15 interview, David R. Challoner, MD, chair of IOM Committee on the Public Health Effectiveness of the <a title="More news about::FDA" href="http://www.cardiovascularbusiness.com/_news/organization/FDA">FDA</a> 510(k) Clearance Process, discussed the origins of the 510(k), the committee’s findings and the subsequent industry response.</p>
<p>Challoner, vice president of health affairs at the University of Florida in Gainesville, said that when the law was first enacted in 1976, its backers&#8217; intent was to bring the industry under regulation, requiring new devices to undergo a premarket approval and giving the old ones a pass.</p>
<p>“In 1976, [legislators] were legitimately afraid, as was the industry, that if you all of a sudden had to test or retest every device already in the marketplace, it would bring the device economy to a screeching halt,” said Challoner. “They said every device on the market gets in free, and everything after gets a predicate to compare to. But we expect—and this was unsaid—that almost everything hence forward will somehow be tested and evaluated for safety and effectiveness.”</p>
<p><a href="http://earlstevens58.files.wordpress.com/2011/08/fda-approval.gif"><img class="alignleft size-full wp-image-4854" title="FDA-Approval" src="http://earlstevens58.files.wordpress.com/2011/08/fda-approval.gif?w=529" alt=""   /></a>The lawmakers decided not to disrupt the 1976 marketplace because they assumed that older devices would eventually be replaced by new ones, Challoner said, but their expectation never came to fruition. “All the while, technology has been rapidly advancing, getting more complicated, and therefore, the substantial equivalence decision gets more and more tenuous.”</p>
<p>The IOM report was released after 18 months of work prompted by an FDA request to evaluate the effectiveness of the 35-year-old law, as well as consider whether or not it has promoted innovation. “We could find no evidence, other than opinion, that the 510(k) did or did not influence innovation,” Challoner said. “If they really want an answer to this question they need an evidence-based study.”</p>
<p>Challoner acknowledged that many manufacturers opposed the IOM recommendation, instead favoring recent FDA reforms to the 510(k) process.</p>
<p>“The device industry will tell you—even before you give them a conclusion—that any change from current practice is going to kill innovation. Well, that’s just nonsense,” Challoner said. “Basically, the industry would consider the shortest possible time frame for clearance as favoring innovation. But we have to develop some new paradigm by which the public’s legitimate interest based on safety and effectiveness is considered.”</p>
<p>One of the major IOM recommendations is to establish and implement <a title="More news about::post-market surveillance systems" href="http://www.cardiovascularbusiness.com/_news/topic/post-market+surveillance+systems">post-market surveillance systems</a>. These could allow less-complete premarket data gathering by industry, Challoner said, supplemented by a more complete and rapidly responding post-market assessment—a “defense early warning system.” Current post-market assessment is too weak, too scattered and lacks appropriately placed responsibility, Challoner said, adding that it is currently only used under particular conditions as required by the FDA.</p>
<p>When asked if there are any circumstances under which substantial equivalence is appropriate for device approval, Challoner said “not as long as substantial equivalence has nothing to do with safety and effectiveness.” However, under a possible new premarket  framework, it may be appropriate to consider post-market data of substantially <a title="More news about::equivalent devices" href="http://www.cardiovascularbusiness.com/_news/topic/equivalent+devices">equivalent devices</a>.</p>
<p>“If the FDA had a post-market surveillance system in place, they could look at the safety and effectiveness data of a <a title="More news about::predicate device" href="http://www.cardiovascularbusiness.com/_news/topic/predicate+device">predicate device</a>,” Challoner said. “That should be part of the evidence package for approving a new device.”</p>
<p>Now that the report has been released, it’s the responsibility of the FDA to manage the conversation, Challoner said, and it’s important that all stakeholders—industry, patient groups, healthcare providers, Congress, the FDA—participate in developing a clearance process for medical devices.</p>
<p>“Start the process, think about the performance characteristics, get all of the parties together, make a recommendation to Congress and get them to approve it,” Challoner said.</p>
<p>The FDA is scheduled to hold a public meeting on the IOM report on Sept. 16.</p>
<div>Last updated on August 16, 2011 at 10:32 am EST</div>
<h6 class="zemanta-related-title" style="font-size:1em;">Related articles</h6>
<ul class="zemanta-article-ul">
<li class="zemanta-article-ul-li"><a href="/2011/08/15/medical-device-aproval-divisive-devices-or-ufc-510k-fda-meets-iom/">Medical Device Aproval &#8211; Divisive Devices or UFC 510(k): FDA Meets IOM</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/08/13/medical-devices-%25e2%2580%2594-balancing-regulation-and-innovation/">Medical Devices &#8211; Balancing Regulation and Innovation</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/07/31/institute-of-medicine-public-health-effectiveness-of-the-fda-510k-clearance-process/">Institute of Medicine &#8211; Public Health Effectiveness of the FDA 510(k) Clearance Process</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/07/31/us-congress-women-rosa-l-delauro-takes-fda-to-task-over-comments-re-iom-report/">US Congress Women Rosa L. DeLauro Takes FDA To Task Over Comments re IOM Report</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/07/31/u-s-advisers-call-for-new-medical-device-regime/">U.S. advisers call for new medical device regime</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/08/02/fda-seeks-public-views-on-proposed-510k-plans/">FDA Seeks Public Views on Proposed 510(k) Plans</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/07/31/510k-approval-process-is-too-big-to-fail-no-matter-how-flawed-it-may-be/">510(k) approval process is too big to fail no matter how flawed it may be</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="http://www.medcitynews.com/2011/08/fdas-510k-program-unfixable-new-england-journal-of-medicine-agrees/">FDA&#8217;s 510(k) program unfixable, New England Journal of Medicine agrees</a> (medcitynews.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/07/30/barry-meier-study-faults-approval-process-for-medical-devices/">Barry Meier &#8211; Study Faults Approval Process for Medical Devices</a> (earlsview.com)</li>
<li class="zemanta-article-ul-li"><a href="/2011/08/04/did-iom-put-the-final-nail-in-the-coffin-of-metal-on-metal-hip-implants/">Did IOM Put the Final Nail in the Coffin of Metal-on-Metal Hip Implants?</a> (earlsview.com)</li>
</ul><br />Filed under: <a href='/category/510k-process/'>510k process</a>, <a href='/category/fda/'>FDA</a>, <a href='/category/fda-510k-process/'>FDA 510k process</a>, <a href='/category/fda-recall/'>FDA Recall</a>, <a href='/category/fda-review-2/'>FDA Review</a>, <a href='/category/fda-warning/'>FDA Warning</a>, <a href='/category/institute-of-medicine/'>Institute of Medicine</a> Tagged: <a href='/tag/federal-food-drug-and-cosmetic-act/'>Federal Food Drug and Cosmetic Act</a>, <a href='/tag/food-drug-administration/'>Food &amp; Drug Administration</a>, <a href='/tag/hip-replacement/'>Hip Replacement</a>, <a href='/tag/institute-of-medicine/'>Institute of Medicine</a>, <a href='/tag/medical-device/'>Medical device</a>, <a href='/tag/public-health/'>Public health</a>, <a href='/tag/united-states/'>UNited States</a>, <a href='/tag/university-of-florida/'>University of Florida</a> <a rel="nofollow" href="http://feeds.wordpress.com/1.0/gocomments/earlstevens58.wordpress.com/4852/"><img alt="" border="0" src="http://feeds.wordpress.com/1.0/comments/earlstevens58.wordpress.com/4852/" /></a> <img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=earlsview.com&#038;blog=7336087&#038;post=4852&#038;subd=earlstevens58&#038;ref=&#038;feed=1" width="1" height="1" />]]></content:encoded>
			<wfw:commentRss>https://earlsview.com/2011/08/18/iom-chair-discusses-510k-report-origins-findings-response/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/6b9f08d281cf2be916ed45fc4fe2ecd7?#38;d=identicon&#38;r=G" medium="image">
			<media:title type="html">earlstevens58</media:title>
		</media:content>

		<media:content url="http://www.cardiovascularbusiness.com/images/assets/Q2hhbGxvbmVyIHYyMjAxMS0wOC0xNiAwMTozMzo1Mg==.jpg" medium="image">
			<media:title type="html"> </media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/institute-of-medicine3.jpg" medium="image">
			<media:title type="html">Institute of Medicine</media:title>
		</media:content>

		<media:content url="http://earlstevens58.files.wordpress.com/2011/08/fda-approval.gif" medium="image">
			<media:title type="html">FDA-Approval</media:title>
		</media:content>
	</item>
	</channel>
</rss>
